









Evaluation of the Mobility 
















An early intervention programme for people  
with musculoskeletal conditions  





Allen + Clarke is grateful to evaluation participants who made themselves available for interviews 
and focus group sessions. The experiences and ideas shared during the evaluation were 
invaluable. We would like to thank the MAP service providers for their interviews and focus group 
session participation, and the Ministry of Health’s MAP project team (Simon Duff, Peter Jones, Julie 
Palmer, Peter Larmer, and Jake Gallagher) for their support with this evaluation. Ngā mihi nui ki 
a koutou katoa. 
 
 
ABOUT ALLEN + CLARKE 
Allen and Clarke Policy and Regulatory Specialists Limited (Allen + Clarke) is a consultancy firm 
with offices in Wellington and Melbourne. We specialise in research and evaluation; policy and 
programme development and implementation; business change; operational management and 
risk; and secretariat and programme support services. Founded in 2001, the company is owned 
and managed by eight senior staff and has a team of over seventy other senior evaluation and 
policy practitioners, analysts and project support staff. Our company works extensively for a 
range of government agencies in New Zealand, Australia, international clients, and non-
government organisations in the Pacific and Asia. More information about our work can be found 







Document status:  Final Cycle 2 Report (Anonymised version) Allen + Clarke has been 
independently certified as 
compliant with ISO9001:2015 
Quality Management Systems 
  
Version and date: V3; 21/01/21 
Author(s): Jessie Wilson, Ross Wilson, Haxby Abbott, 
Brendan Stevenson, Marnie Carter, Yasmine 
Kayem 
Filing Location: W:\MOH Service Commissioning\Evaluation of 
MAP AOG-MOH059MAP\3 Evaluation cycle 2\8 
Reporting\Drafts of draft Cycle 2 report 




QA changes made: 
Jessie Wilson 
Proof read: Pounamu Aikman 
Formatting: Pounamu Aikman 










ABOUT ALLEN + CLARKE II 
CONTENTS 3 
TABLE OF FIGURES 5 
TABLE OF TABLES 7 
EXECUTIVE SUMMARY 9 
1. INTRODUCTION 18 
2. EVALUATION FINDINGS 3 
2.1. MAP cohort demographics 3 
2.2. Health outcomes 9 
2.3. Reach 26 
2.4. Reduction in disparities 29 
2.5. Economic impact 41 
2.6. Consumer experience 49 
2.7. What works best 53 
3. EVALUATION CONCLUSIONS 56 
4. RECOMMENDATIONS 61 
APPENDIX A: GLOSSARY 63 
APPENDIX B: ABOUT THE MOBILITY ACTION PROGRAMMES 65 
 
26 
APPENDIX C: DESIRED ACHIEVEMENTS AND EVALUATIVE ASSESSMENTS 74 
APPENDIX D: MAP PROVIDER AND MAP CHARACTERISTICS 83 
APPENDIX E: MAP EVALUATION CYCLE 2 DATA COLLECTION METHODS 85 





 Mobility Action Programme (MAP) Evaluation Cycle 2 Draft Final Report 25 
TABLE OF FIGURES 
Figure 1: Change in BMI between Time 1 and Times 2 through 4, by programme 12 
Figure 2: Change in NPRS scores between Time 1 and Times 2 through 4, by programme 14 
Figure 3: Change in TU&G scores between Time 1 and Time 2, by programme 15 
Figure 4: Change in LEFS scores between Time 1 and Times 2 through 4, by programme 16 
Figure 5: Change in OHS scores between Time 1 and Times 2 through 4, by programme 16 
Figure 6: Change in OKS scores between Time 1 and Times 2 through 4, by programme 17 
Figure 7: Change in QuickDASH scores between Time 1 and Times 2 through 4, by programme 18 
Figure 8: Change in RMDQ scores between Time 1 and Times 2 through 4, by programme 18 
Figure 9: Change in NDI scores between Time 1 and Time 2, by programme 19 
Figure 10: Change in SSES scores between Time 1 and Times 2 through 4, by programme 19 
Figure 11: Change in PCS scores between Time 1 and Times 3 and 4, by programme 22 
Figure 12: Change in MCS scores between Time 1 and Times 3 and 4, by programme 23 
Figure 13: Change in SF-6D values between Time 1 and Times 3 and 4, by programme 24 
Figure 14: Contracted vs actual enrolment numbers, by programme 26 
Figure 15: MAP completion rates, by time point and programme 27 
Figure 16: Change in NPRS scores between Time 1 and Times 2 through 4, priority groups 36 
Figure 17: Change in SSES scores between Time 1 and Times 2 through 4, priority groups 37 
Figure 18: Change in TU&G scores between Time 1 and Times 2 through 4, priority groups 37 
Figure 19: Change in OHS scores between Time 1 and Times 2 through 4, priority groups 37 
Figure 20: Change in OKS scores between Time 1 and Times 2 through 4, priority groups 38 
 
26 
Figure 21: Change in RMDQ scores between Time 1 and Times 2 through 4, priority groups 38 
Figure 22: Change in LEFS scores between Time 1 and Times 2 through 4, priority groups 38 
Figure 23: Change in SF-12 PCS scores between Time 1 and Times 2 through 4, priority groups 39 
Figure 24: Change in SF-12 MCS scores between Time 1 and Times 2 through 4, priority groups 39 
Figure 25: Change in SF-6D values between Time 1 and Times 2 through 4, priority groups 39 
Figure 26: Projected MAP cohort health gains; 1-, 3-, 5-, 10-, and 15-year time horizons 44 
Figure 27: Projected MAP cohort incremental healthcare costs; 1-, 3-, 5-, 10-, and 15-year time horizons 45 
Figure 28: Projected MAP cohort incremental net monetary benefit; 1-, 3-, 5-, 10-, and 15-year time horizons 46 
Figure 29: MAP wait times per provider 50 
Figure 30: Happiness with MAP experience 51 





 Mobility Action Programme (MAP) Evaluation Cycle 2 Draft Final Report 25 
TABLE OF TABLES 
Table 1: MAP evaluation criteria and questions 11 
Table 2: MAP evaluation criteria and questions 20 
Table 3: Summary of MAP evaluation Cycle 2 data collection methods 1 
Table 4: MSK diagnoses of MAP participants (counts and percentages) 6 
Table 5: Baseline characteristics of total MAP cohort (N = 4,783) (counts and percentages) 6 
Table 6: Overview of health outcome measures used in the MAP 9 
Table 7: Change in health outcomes relative to baseline (Score and 95% CI) 10 
Table 8: Self-reported learnings from MAP (counts and percentages) 13 
Table 9: Enrolment by provider and priority groups (counts and percentages) 31 
Table 10: Percentage of each priority population in the MAP participant cohort compared to the estimated proportion of the total population with OA within the 
geographic area 32 
Table 11: Discharge volumes (and percentages of baseline enrolment) by provider and priority population 33 
Table 12: Provider strategies to retain MAP priority groups 35 
Table 13: Change in mean number of medical events reported between Time 1 and Times 2 through 4 (mean and 95% CI) 42 
Table 14: Baseline characteristics of the MAP and MOA trial samples (score and S.E.) 43 
Table 15: Change in MAP participants’ work status between Time 1 and Times 2 through 4 (percentages and 95% CI) 47 
Table 16: MAP wait times before starting the programme (counts and % responding) 49 
Table 17: MAP evaluation rubric 81 
Table 18: Number of MAP participants with recorded data, by programme and time point 87 
Table 19: Health outcomes at each time point (number of respondents in brackets) 88 
Table 20. Logistic Regression Coding. 93 
 
26 
Table 21: Consumer survey demographic breakdown: Age x Gender. 93 
Table 22. Consumer survey demographic breakdown: Ethnicity (counts and percentages). 94 
Table 23. Time since MAP completion (counts and percentages). 94 





 Mobility Action Programme (MAP) Evaluation Cycle 2 Draft Final Report 25 
EXECUTIVE SUMMARY 
Background and evaluation purpose 
As the leading cause of disability in New Zealand, musculoskeletal (MSK) conditions generate health, social, and economic strains on individual quality of life 
and health system costs. Research indicates that one in every four adults is affected by MSK conditions, which include arthritis, osteoporosis, lower back pain, 
spinal disorders and injuries to the spine and limbs.1 MSK conditions are not fatal but come at a significant cost to the physical and holistic wellbeing and 
quality of life of those affected. 
New Zealanders affected by MSK conditions can access a range of health services in primary and secondary healthcare settings. However, the management 
of chronic MSK conditions is largely episodic, uncoordinated, and often lacks a strong evidence base.2 The management and treatment of MSK conditions is 
costly; in 2009 it was estimated to comprise at least 25 percent of New Zealand’s total annual health costs.3  
As a key health priority for the Ministry of Health (the Ministry), Budget 2015 confirmed a total of $50 million to be invested over the 2015/16 to 2017/18 
financial years to improve prevention and treatment for people with orthopaedic and MSK conditions, and to provide more New Zealanders with timely 
access to planned care. Of this, $44 million was targeted to support extra orthopaedic and general surgeries, and $6 million to improve care for people with 
MSK conditions by delivering early-intervention, community-based programmes. 
The Mobility Action Programme (MAP) was developed by the Ministry as part of this $6 million investment. The MAP was designed to align with best practice 
approaches to early intervention programmes for MSK conditions and the five themes of the New Zealand Health Strategy.4,5 The MAP aimed to deliver 
evidence informed, community-based, multidisciplinary interventions for adults with MSK conditions. It intended to support people to access advice, 
assessment and treatment earlier than had previously been available. The MAP’s priority groups were Māori, Pasifika and individuals living in the highest 
deprivation quintile. The programme ran from May 2016 to December 2019. During this time, 4,783 individuals participated in the programme.  
 
1 Bosley, C., & Miles, K. (2009). Musculo-skeletal Conditions in New Zealnd: The Crippling Burden. The Bone & Joint Decade 2000-2010: Wellington.  
2 Sourced from contract service specifications between the Ministry of health and the MAP providers.  
3 Bosley, C., & Miles, K. (2009). Musculo-skeletal Conditions in New Zealnd: The Crippling Burden. The Bone & Joint Decade 2000-2010: Wellington. 
4 The MAP was designed based on best practice approaches for early intervention programmes such as Australia’s Osteoarthritis Chronic Care Programme; Britain’s National 
Institute for Health and Clinical Excellence; the Osteoarthritis Research Society International; and the European Action Towards Better Musculoskeletal Health. 
5 New Zealand Health Strategy strategic themes include: 1) People-powered; 2) Closer to home; 3) Value and high performance; 4) One team; and 5) Smart system. 
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The key objectives of the MAP were to improve the holistic well-being of adults who experience MSK conditions, reduce demand on secondary healthcare 
services, and address health inequity. It also aimed to provide evidence on the effectiveness of early intervention programmes targeting MSK conditions in 
the New Zealand context.  
The Ministry established a total of 17 MAP pilot sites (MAPs). The first group of MAPs, involving seven providers, was initiated in May 2016 (Tranche 1 
service providers). The second group, involving ten providers, was established in November 2016 (Tranche 2 service providers). All MAPs were designed to 
provide early intervention models of care, except for one MAP pilot site that targeted individuals in the later stages of their condition.6   
The Ministry selected a range of providers to deliver the pilot MAPs. These included Non-Government Organisations (NGOs), private providers (such as 
physiotherapists, occupational therapists, and psychologists), Māori and Pasifika health providers, District Health Boards (DHBs) and Primary Health 
Organisation (PHOs). Providers were selected based on a range of criteria (e.g., ability to address inequity, and/or meet the unique socio-cultural and health 
needs of those with MSK conditions within their service areas). 
The Ministry commissioned Allen + Clarke to evaluate the effectiveness and impact of the MAP, and to provide an evidence base that identifies the models 
and approaches that best achieve the programme’s intended outcomes. The evaluation consists of two cycles.7 This report describes findings from both 
cycles, with data collected from April 2018 to December 2019.  
Evaluation results will be used to inform future investment in MAP-type programmes by the Ministry, DHBs, PHOs and/or other potential funders such as 
the Ministry of Social Development (MSD), the Accident Compensation Corporation (ACC) and private organisations. The findings will also help inform 
decisions about which MAPs, and which components of the MAPs will be continued, changed or stopped.  
Methodology 
The evaluation examined the effectiveness and impact of the MAP across six domains or evaluation criteria. These are: (1) health outcomes; (2) reach; (3) 
reduction in disparities; (4) economic impact; (5) consumer experience; and (6) what ‘works best’. The following key evaluation questions (KEQs) are framed 
around these criteria.  
 
6 One programme targeted individuals who were in the later stages of their condition and had already been referred for specialist assessment. 
7 Cycle 1 occurred over 2018 and involved analysis of participant data and case studies with MAP service providers. Cycle 2 included additional focus group sessions with 
MAP service providers and an in-depth analysis MAP participant data. 
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Table 1: MAP evaluation criteria and questions 
Evaluation criteria Key evaluation questions  
Health outcomes 1. What impact has the MAP had on general health status, pain, functional status, self-confidence and ability of participants to 
self-manage their condition? 
Reach 2. To what extent has the MAP reached its anticipated (contracted) enrolment and completion rates? 
Reduction in disparities 3. To what extent is the MAP reducing known disparities in access to health services and outcomes? 
Economic impact 4. What was the economic impact of the programme? 
Consumer experience 5. How well has the programme managed patient care? 
What works best  6. Under what conditions does the programme work best? 
Overview of evaluation findings 
Health outcomes 
Participants in the MAP increased healthy behaviours and experienced reduced pain, enhanced mobility and functionality, enhanced wellbeing and reduced 
need for secondary healthcare services.   
Overall evaluation findings indicate that participation in the MAP (across either all or most MAPs) contributed to: 
• a maintained reduction in Body Mass Index (BMI); 
• significant improvements in health-related behaviour changes; 
• significant reductions in pain and improvements in mobility and functionality; 
• significant improvements in participants’ perceived ability and confidence to self-manage their conditions; 
• significant improvements in general health and wellbeing; and 




The MAP was largely effective in reaching its target groups. Programme completion rates were less than anticipated. 
Reach is defined as the extent to which the MAPs achieved their anticipated (i.e., contracted) participant enrolment volumes and anticipated discharge rates 
(i.e., until the end of the programme, or Time 2). 
Evaluation findings about the reach of the MAP indicate that: 
• most providers achieved 80 percent of their enrolment target; 
• in nine out of the seventeen providers, 80 percent of participants remained in the programme until completion; 
• factors contributing to non-completion included: inappropriate referrals; participants experiencing comorbidities and complex needs; 
administrative and logistical challenges with follow-ups; the amount of health outcome information providers were required to collect; a lack of 
capacity from some providers to build new systems, processes, structures and resources for participant follow-ups from scratch; and participants 
not understanding or buying into the purpose of the follow-ups; and 
• providers’ strategies to enhance the reach of the programme and mitigate non-completion included: visiting workplaces, marae and homes; building 
rapport with participants from the outset and incorporating follow-ups into the core programme from the beginning; being flexible and empowering 
participants to decide where and when follow-ups would best work for them; and offering incentives for programme completion. 
Reduction in disparities 
The MAP effectively reached Māori, Pasifika and those living in high deprivation, but struggled to retain these priority groups to completion. These groups 
achieved similar health outcomes to the general MAP cohort. 
The evaluation explored the extent to which the MAP reduced disparities in access to health services and outcomes. This was assessed by exploring: (1) 
strategies providers used to reach the programme’s priority groups (e.g., Māori, Pasifika and individuals living in the highest deprivation quintile);8,9 (2) 
whether the needs of priority groups were met; and (3) whether priority groups experienced equity of outcomes when compared to the general MAP cohort.  
Evaluation findings regarding reducing disparities through the MAP show: 
 
8 The New Zealand Health Survey 2013/14 shows that Māori and Pacific adults were 1.3 times more likely to have arthritis than non-Māori and non-Pacific adults. 
9 Arthritis UK (2014) reports that individuals living in high deprivation are more likely to report chronic pain, and the pain they experience is likely to be more severe. 
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• the MAP successfully enrolled Māori, Pasifika and those living in deprived neighbourhoods; 
• priority groups were less likely to remain with the MAP until discharge (Time 2). Only three MAPs achieved completion rates for Māori at or above 
the rate for all participants and only one achieved similar completion rates for Pasifika; 
• participation rates for priority groups were generally similar to, or greater than, the estimated proportion of those populations with MSK conditions 
within their geographical region;  
• there were few significant differences in health outcomes between priority groups and other participants, but Pasifika participants had worse 
outcomes on mental health and general health-related quality of life (at Time 4/12 months after discharge only); 
• the MAP participant survey results show that respondents who identified as Māori were 1.9 times more likely to report learning how to manage their 
weight than non-Māori, 3.6 times more likely to report health improvements and 3 times more likely to report an improved ability to seek or return 
to working following MAP; and 
• successful strategies used to target priority groups include developing relationships with iwi, Māori organisations and employers with largely Māori 
workforces; educating referrers on the MAP’s priority groups and eligibility criteria; and employing staff with cultural competency and te reo Māori 
and Pasifika language skills.  
Economic impact 
The MAP offers value for money. The programme is projected to be highly cost-effective over a five-year horizon. 
The cost-effectiveness of the MAP was assessed comparing results with the New Zealand Management of OsteoArthritis (NZ-MOA) model. The design of the 
MAP did not include a control group to allow an estimate of its cost-effectiveness. To assessment economic impact, MAP participant data was supplemented 
with previously collected randomised trial data of similar patients (predominantly early- to mid-stage OA) and a similar intervention (the MOA trial).10 
Participants in the MOA trial were randomly assigned to either a ‘usual care’ control group, in which they continued to receive the usual medical care provided 
by their GP and other healthcare providers; or an exercise therapy intervention group.  
 
10 The findings should be interpreted with some caution, as the MAP and MOA interventions have key differences, including different inclusion criteria, target conditions 




The cost-effectiveness of the MAP was estimated using the previously validated NZ-MOA computer simulation model of the disease course, health losses, and 
treatment costs of MSK conditions in the NZ population (see Appendix E page 89 for further details). Cost-effectiveness analyses suggested that: 
• the MAP was projected to be highly cost-effective over a five-year horizon; 
• there was more uncertainty in the projected longer-term outcomes, but the cumulative health gain over five years was projected to be 549 QALYs 
with cost savings of $4.3 million; 
• total health gains were estimated to be 155 quality-adjusted life years (QALYs)11 in the MAP cohort or 0.03 per participant; and 
• costs from budgeted per-participant costs were estimated at $743 per participant ($3.6 million total), resulting in incremental net monetary benefit 
(INMB)12 of $5.4 million, indicating the MAP was cost-effective over the short-term from the perspective of the healthcare system; 
MAP consumer survey results offered additional support of the programme’s cost-effectiveness and contributions to enhanced productivity: 
• 54 percent of survey respondents stated that attending the MAP reduced their medical costs;  
• 59 percent of respondents reported improvements in their ability to either work or to seek work, with those identifying as Māori three times more 
likely than non-Māori to report an improvement; and 
• MAP participants were less likely to report negative effects of their condition on their work/volunteer time and were less likely to be unemployed 
for condition-related reasons. 
Consumer (MAP participant) experience 
The MAP mostly met consumer needs and expectations and helped them self-manage their conditions. 
An anonymous survey of all MAP consumers was administered to the entire MAP cohort.13 The purpose of the survey was to obtain quantifiable data 
regarding the consumer experience of the MAP. In total, 1,019 clients from a possible 3,453 (29.5 percent) completed the survey.  Analysis of survey data on 
the consumer experience found that: 
 
11 QALYs are a measure that quantifies the health effect of an intervention or programme by combining improvement in health-related quality of life and the length of time 
spent with improved health. One QALY equates to a year of life lived in perfect health. 
12 The INMB is a measure of the overall cost-effectiveness of an intervention, assuming a given willingness-to-pay for healthcare to achieve a given health gain. 
13 This includes both completers and non-completers.  
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• overall, the majority (86 percent) were happy with their MAP experience; 
• wait times for enrolling in a MAP were generally between one to two months and most respondents perceived this wait time as acceptable; 
• 76 percent of respondents understood the MAP’s purpose before starting the programme, though some would have liked additional information 
about the programme, specific courses and programme availability;  
• most respondents reported that programme locations and days/times of sessions suited them and their conditions; and 
• nearly all were comfortable with how staff talked to them during MAP classes, appointments, and the way MAP was explained to them. 
What programme characteristics/models of care work best 
Features associated with programme success are group sessions, longer duration and delivered by both private providers and a mix of provider types. 
Cycle 2 of the evaluation emphasised the evaluation criterion “What works best”. The evaluation found that: 
• private providers performed best in achieving improvements in participant health and offered accessibility and flexibility for MAP participants; 
• a mix of provider types (e.g., DHBs and NGOs) performed better in achieving their contracted enrolment volumes; 
• group sessions were more effective than individual sessions in achieving health outcomes and performed best in retaining participants until 
completion; and 
• longer-duration programmes (10 weeks and more) had consistently larger improvements in all health outcomes and offered better healthcare gains, 
savings and cost-effectiveness.  
Other features associated with MAP effectiveness include: 
• programmes delivered by providers accustomed to interdisciplinary care models; 
• providers with experience in working with the priority population groups; 
• building in time at the beginning of the programme to build relationships between providers, referrers and community groups; 
• ensuring there are effective triaging services at the point of programme referral; 
• incorporating an equity focus into the programme, and implementing specific strategies to target priority groups and to meet their specific health, 
social and cultural needs; 
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• ensuring programmes are delivered in convenient locations, close to transport and with a range of session times including evenings or weekends; 
• meeting with participants individually at the beginning of the programme to build buy-in and understanding and to collaboratively design an 
individual care plan; 
• emphasising participant self-management of their conditions; and 
• setting expectations around attendance upfront, and offering an easy-to-follow, structured programme. 
Conclusion 
The evaluation provides strong evidence that the MAP is an effective early intervention programme for people with MSK conditions. The MAP has resulted 
in health outcome gains for its participants, with the priority population groups achieving similar or better improvements in health status.  
The evaluation has also demonstrated that the programme is a prudent investment, with evidence showing it was cost-effective over the short-term, 
achieving estimated health gains of 155 QALYs in the MAP cohort, and INMB of $5.4 million. The MAP is projected to be highly cost-effective over a five-year 
horizon.  
The evaluation concludes that investment in early intervention programmes for MSK conditions represents value for money. The specific focus of the MAP 
on priority groups contributes to health equity for Māori, Pasifika and those living in areas of higher derivation. 
Recommendations 
Based on the findings and conclusions described in this report, the evaluation makes the following recommendations: 
1. The evaluation recommends an expanded roll out of the MAP, or similar programmes. 
2. Models should incorporate the features that have been shown to be effective (i.e. group sessions, longer duration, delivered by both private providers 
and mixed entity provider).  
3. Focus on improving programme completion rates for priority populations. 
4. Strategies that ensure equity of outcomes for Pasifika should be a core component of the programme. 
5. Consider adapting the programme for participants with comorbidities and/or complex needs. 
6. Offer opportunities for post-programme support to embed self-management behaviours. 
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1.1. Background and context 
As the leading cause of disability in New Zealand, MSK conditions generate a significant health, social, and economic strain on both individual quality of life 
and health system costs. Research indicates that one in every four adults are affected by MSK conditions, which include arthritis, osteoporosis, lower back 
pain, spinal disorders and injuries to the spine and limbs.14 MSK conditions are not fatal but come at a significant cost to the physical and holistic wellbeing 
and quality of life of those affected. 
New Zealanders affected by MSK conditions can access a range of health services through primary and secondary healthcare settings. However, the 
management of chronic MSK conditions is largely episodic, uncoordinated, and often lacks a strong evidence base.15 The management and treatment of MSK 
conditions is costly; in 2009 it was estimated to comprise at least 25 percent of New Zealand’s total annual health costs.16  
As a health priority for the Ministry of Health (the Ministry), Budget 2015 confirmed a total of $50 million be invested over the 2015/16 to 2017/18 financial 
years in New Zealand to improve prevention and treatment for people with orthopaedic and MSK conditions, and to provide more New Zealanders with 
timely access to elective surgery. A $44 million investment aimed to support extra orthopaedic and general surgeries, and a $6 million allocation aimed to 
improve care for people with MSK health conditions by delivering early-intervention, community-based programmes. 
The Mobility Action Programme (MAP) was developed by the Ministry as part of this $6 million investment. The MAP was designed to align with best practice 
approaches to early intervention programmes for MSK conditions and the five themes of the New Zealand Health Strategy.17,18 The design of the MAP was 
guided by an Expert Advisory Group. The multi-disciplinary group included specialists in rehabilitation, rheumatology, exercise, nutrition, orthopaedics, 
physiotherapy, pharmacology, primary care, nursing, as well as representatives from ACC and consumers. The MAP aimed to deliver community-based 
interventions for adults experiencing MSK conditions so that high quality advice, assessment and treatment could be provided earlier than had previously 
been available.  
 
14 Bosley, C., & Miles, K. (2009). Musculo-skeletal Conditions in New Zealnd: The Crippling Burden. The Bone & Joint Decade 2000-2010: Wellington.  
15 Sourced from contract service specifications between the Ministry of health and the MAP providers.  
16 Bosley, C., & Miles, K. (2009). Musculo-skeletal Conditions in New Zealnd: The Crippling Burden. The Bone & Joint Decade 2000-2010: Wellington. 
17 The MAP was designed based on best practice approaches for early intervention programmes such as Australia’s Osteoarthritis Chronic Care Programme; Britain’s National 
Institute for Health and Clinical Excellence; the Osteoarthritis Research Society International; and the European Action Towards Better Musculoskeletal Health. 
18 New Zealand Health Strategy strategic themes include: 1) People-powered; 2) Closer to home; 3) Value and high performance; 4) One team; and 5) Smart system. 
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The key objectives of the MAP were to address health inequity; reduce demand on secondary healthcare services; and improve the holistic wellbeing of adults 
who experience MSK conditions.  
The Ministry selected a range of providers to deliver the pilot MAPs. These included Non-Government Organisations (NGOs), private providers (such as 
physiotherapists, occupational therapists and psychologists), Māori and Pasifika health providers, District Health Boards (DHBs) and Primary Health 
Organisation (PHOs). Providers were selected based on a range of criteria (e.g., ability to address inequity; and/or meet the unique socio-cultural and health 
needs of those who suffer from MSK conditions within their respective service areas). 
The first group of MAPs, involving seven providers, was initiated in May 2016 (Tranche 1 service providers). A further ten pilot programmes were initiated 
late 2016/early 2017 (Tranche 2 service providers). The 17 MAPs varied in size, approach, duration, structure, price, populations targeted, conditions 
treated, localities and type of services provided. All MAPs were designed to provide evidence informed, community based, multidisciplinary early 
intervention models of care, except for one MAP pilot site that targeted individuals in the later stages of their condition.19   
1.2. Evaluation purpose 
The evaluation was commissioned by the Ministry to assess the effectiveness and impact of the MAP. The purpose was to identify the most effective ways to 
deliver these programmes and how to organise care so that those who need it receive it equitably. The evaluation also offers evidence on effective models of 
care for early treatment of MSK conditions. The results are intended to inform decisions regarding which MAP models or components of models are 
recommended to be sustained or scaled up beyond the pilot.  
1.3. Methods 
The MAP was evaluated against six key evaluation domains (or “criteria”): (1) health outcomes; (2) reach; (3) reduction in disparities; (4) economic impact; 
(5) consumer experience; and (6) what works best. Further to exploring the six evaluation domains, the evaluation was nested within the broader 
government aims of building a stronger public healthcare system and more equitable outcomes for all New Zealanders.20 
The following key evaluation questions (KEQs) and sub-questions were framed around these criteria. 
  
 
19 One programme targeted individuals who were in the later stages of their condition, and had already been referred for specialist assessment. 
20 See also https://www.beehive.govt.nz/feature/our-plan-modern-new-zealand-we-can-all-be-proud for the Government’s priorities for New Zealand.  
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Table 2: MAP evaluation criteria and questions 
Evaluation criteria Key evaluation questions and sub-questions 
Health outcomes 1. What impact has the MAP had on general health status, pain, functional status, self-confidence, and ability of participants to self-
manage their condition? 
Reach 2. To what extent has the MAP reached its anticipated (contracted) enrolment and completion rates? 
2.1. What are the reasons for non-completion? 
Reduction in disparities 3. To what extent is the MAP reducing known disparities in access to health services and outcomes? 
3.1. How equitable is access to the MAP across demographic variables (ethnicity, deprivation)? 
3.2. To what extent has participation in the MAP reduced health outcome disparities in people with MSK health conditions? 
Economic impact 4. What was the economic impact of the programme? 
4.1. To what extent does the MAP offer value for money? 
4.2. What economic impacts has the MAP contributed to (such as keeping people in employment, improving productivity, and 
enabling people to return to the workforce)? 
4.3. What impact has the MAP had on health system and participant financial costs? 
4.4. To what extent is the MAP a sustainable economic model that will remain viable into the future?  
Consumer experience 5. How well has the programme managed patient care? 
5.1. To what extent does the MAP meet patient care expectations? 
5.2. How effective and appropriate is the MAP consumer experience, from service entry to exit? 
5.3. What has changed for patients in the short term (on completion of the MAP, 3 months and 12 months following completion)?  
What works best  6. Under what conditions does the programme work best? 
6.1. Which structures, approaches and programme components provide the greatest benefits? 
6.2. What enablers/barriers/factors contributed to the success or otherwise of the MAP? 
6.3. What models or components should be sustained, scaled up, adopted and adapted to areas beyond the initial MAP locations? 
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Evaluation criteria Key evaluation questions and sub-questions 
6.4. How could the programme be improved from a consumer, provider and funder perspective? 
To answer the KEQs, the evaluation separated each criterion into standards of performance to identify the desired achievements of the MAP. The evaluation 
team used these performance standards to guide its assessment of whether the desired achievements of the MAP were realised. The desired achievements, 
performance standards, and evaluation rubric are provided in Appendix C: Desired Achievements and Evaluative Assessments. 
The evaluation included both qualitative and quantitative data collection methods across two collection cycles. This report incorporates findings from both 
Cycle 1 and Cycle 2. 
Cycle 1 occurred between April and May 2018 and involved:21 
• 11 key informant interviews;  
• five case studies;  
• three virtual focus groups with MAP providers;  
• development and release of a MAP consumer survey targeting all MAP participants; and 
• analysis of MAP participant health outcomes data across various timepoints and participant- (e.g., gender, age, ethnicity) and programme-level (e.g., 
co-payment, provider location) characteristics. 
Cycle 2 took place between May 2018 – December 2019 and involved: 
• a follow-up interview with the Ministry’s MAP stakeholders; 
• four follow-up virtual focus groups with MAP providers; 
• analysis of the MAP consumer survey data; 
 
21 Allen and Clarke (2018). Evaluation of the Mobility Action Programme (MAP): Cycle 1 Final Report. 




• re-analysis of MAP participant health outcomes data with additional 12-month follow-up data across various timepoints and participant- and 
programme-level characteristics; and 
• analysis of the health, economic and cost-effectiveness of the MAP using the New Zealand Management of Osteoarthritis (NZ-MOA) model, a 
population-based microsimulation model. 
Cycle 2 emphasised the evaluation criterion “What works best” and the associated key evaluation questions depicted in Table 2 (e.g., identification of the most 
effective implementation approaches and examination of factors that contributed to the success or otherwise of these.). Cycle 2 categorised the 17 MAPs into 
four programme-level characteristics and explored how these characteristics affected outcomes across the evaluation criterion (see Appendix D): 
• provider type (private rehabilitation organisation, mix of agencies including DHBs and NGOs); 
• delivery method (group, individual, mix of group and individual); 
• programme duration (10 or less weeks, 11 or more weeks); and 
• main referral source (GP, self-referral, other referral source). 
Details about the data collection and analysis methods used for Cycle 2 are provided in Appendix D: MAP Provider and MAP Characteristics 









Short ≤ 10 
weeks 




Programme 1              
Programme 2              
Programme 3            
Programme 4              
Programme 5              
Programme 6             
 
 
 Mobility Action Programme (MAP) Evaluation Cycle 2 Draft Final Report 25 
Programme 7             
Programme 8               
Programme 9              
Programme 10           
Programme 11             
Programme 12             
Programme 13              
Programme 14              
Programme 15              
Programme 16             
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Appendix E: MAP Evaluation Cycle 2 Data collection methods and summarised in the following 
table. 
Table 3: Summary of MAP evaluation Cycle 2 data collection methods 
Data Collection method Method summary 
Follow-up interview with Ministry staff One interview with three individuals. 
Virtual focus groups with MAP providers Four focus groups with 25 individuals across MAP service 
providers. 
Re-analysis of MAP participant data Re-analysis of MAP participant data across four time points: 
Entry into the programme (Time 1); discharge from the 
programme (Time 2); three-month follow-up (Time 3); and 
12-month follow-up (Time 4).22  
 
Key participant- and programme-level characteristics across 
health outcomes are also explored. Statistically significant 
results are reported. 
NZ-MOA analysis Model utilises three data inputs to simulate MAP’s potential 
future health, economic and cost-effectiveness: 
1) MAP participant health outcome data;  
2) data from a New Zealand-based, randomised control trial 
of exercise therapy for a similar MSK conditions intervention 
(the MOA trial); and  
3) census data for the 2017 New Zealand population. 
1.4. Limitations 
Some limitations are noted for Cycle 2 of the MAP evaluation. 
Firstly, as with all qualitative work, the views collected by evaluation stakeholders cannot 
completely representative or generalisable to all individuals involved in the programme.  
Secondly, the design of the MAP did not provide for the identification of a control group. 
Comparison with an appropriate control group would make estimation of the programme’s 
effectiveness and impact more statistically robust. Although true treatment effects cannot be 
conclusively demonstrated without inclusion of a control group, the evaluation has supplemented 
MAP participant data with previously collected randomised trial data of similar patients 
(predominantly early- to mid-stage OA) and an exercise therapy intervention (the MOA trial). 
While differences in the design of the two interventions means that findings should be interpreted 
with caution, comparison of outcomes does allow for an estimation of the cost effectiveness of the 
MAP. 
 
22 More complete MAP participant data for Time 3 and Time 4 were available for analysis in Cycle 2 
compared to Cycle 1. For further information see Section 2.1, Section 2.2 and Appendix E. 
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1.5. Structure of the report 
Section 2 of this report presents findings from Cycle 1 and Cycle 2 in alignment with the evaluation 
criteria, the key evaluation questions, and the desired achievements of the programme (see 
Section 1.3). Section 3 provides overall conclusions and evaluative assessments for each key 
evaluation question.  
Section 4 presents recommendations for the Ministry and other key stakeholders for potential 
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2. EVALUATION FINDINGS 
The following section describes the MAP cohort and details findings from evaluation of the MAP. 
Section 2.1 presents overall health outcome measures for the entire MAP participant cohort to 
December 2019 (N = 4,783 individuals). Evaluation findings are included on the general health 
status, pain, functional status, and ability of participants to self-manage their condition across 
providers and participant demographics (where relevant and where findings are available).  
2.1. MAP cohort demographics  
The 17 MAPs varied in participant numbers, from between 93 (Programme 3) and 486 
(Programme 12) participants. 
Participants’ ages also varied by programme. Of those participants for whom age information was 
available (N = 4,645, 97 percent), most were aged between 55 and 74 years (N = 2,669; 57 
percent); 1,291 (28 percent) were aged under 55 years; and 685 (15 percent) were aged 75 and 
older.23  
Programme 9 (74 percent) and Programme 15 (50 percent) had substantially higher proportions 
of younger participants (aged under 55), while Programme 11 (29 percent), Programme 12 (27 
percent), Programme 13 (27 percent), Programme 6 (27 percent) and Programme 3 (26 percent) 
programmes had the highest proportion of participants aged 75 and over. 
Most participants were women (N = 3,141; 67 percent in the total sample); ranging from 55 
percent in Programme 15 to 75 percent in Programme 13.  
Most MAP participants were overweight, with a Body Mass Index (BMI) of between 25 and 
30kg/m2 (N = 1,315; 28 percent) or obese, with a BMI greater than 30kg/m2 (N = 2,608; 56 
percent).  
Of those MAP participants with valid diagnosis data, the most common diagnosis was 
osteoarthritis or OA (N = 3,670, 77 percent), followed by back pain (N = 479; 10 percent); 
knee/hip pain without a recorded diagnosis (N = 252; 5 percent); and gout (N = 55; 1 percent). A 
total of 292 participants (6 percent) had an ‘other’ diagnosis that could not be matched to any of 
these conditions.  
OA was the most common diagnosis in 13 of the 17 MAPs ( 
  
 
23 Information about age was grouped in 5-year age bands. 
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Table 4). Exceptions to this were programmes provided by Programme 1 (back pain); Programme 
7 (back pain with large numbers of OA and ‘other’); Programme 9 (‘other’, with large numbers of 
OA and back pain); and Programme 10 (knee/hip pain without OA diagnosis). Programme 13 was 






Table 4: MSK diagnoses of MAP participants (counts and percentages) 
Programme OA Back pain Knee/hip 
pain, no 
OA  
Gout Other Total 
Programme 1 6 (2%) 236 (86%) 2 (1%) 0 (0%) 31 (11%) 275 
Programme 2 458 (100%) 0 (0%) 1 (0%) 0 (0%) 0 (0%) 459 
Programme 3 85 (92%) 6 (7%) 1 (1%) 0 (0%) 0 (0%) 92 
Programme 4 139 (93%) 0 (0%) 7 (5%) 0 (0%) 3 (2%) 149 
Programme 5 291 (78%) 57 (15%) 17 (5%) 0 (0%) 7 (2%) 372 
Programme 6 161 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 161 
Programme 7 43 (23%) 80 (42%) 23 (12%) 2 (1%) 43 (23%) 191 
Programme 8 296 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 296 
Programme 9 105 (32%) 79 (24%) 0 (0%) 0 (0%) 143 (44%) 327 
Programme 10 63 (27%) 3 (1%) 115 (49%) 53 (22%) 2 (1%) 236 
Programme 11 333 (81%) 18 (4%) 8 (2%) 0 (0%) 51 (12%) 410 
Programme 12 471 (98%) 0 (0%) 11 (2%) 0 (0%) 1 (0%) 483 
Programme 13 54 (53%) 0 (0%) 47 (47%) 0 (0%) 0 (0%) 101 
Programme 14 243 (99%) 0 (0%) 2 (1%) 0 (0%) 0 (0%) 245 
Programme 15 309 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 309 
Programme 16 364 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 364 
Programme 17 249 (90%) 0 (0%) 18 (6%) 0 (0%) 11 (4%) 278 
Total 3670 (77%) 479 (10%) 252 (5%) 55 (1%) 292 (6%) 4748 
Note: 35 participants (1 percent) did not have diagnosis data available. 
Comorbidities were common among participants, with 3,188 (67 percent) having at least one 
comorbid condition and 1,598 (34 percent) having at least two comorbid conditions. The most 
common comorbid conditions were high blood pressure (N = 1,763; 37 percent), diabetes (N = 
677; 14 percent), heart disease (N = 642; 14 percent), and depression (N = 625; 13 percent). 
Table 5 summarises key baseline characteristics for the 4,783 individuals in the total sample. 
Table 5: Baseline characteristics of total MAP cohort (N = 4,783) (counts and percentages) 
Characteristic Value 
Comorbid Health Conditions 
High Blood Pressure 1763 (37%) 
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Characteristic Value 
Diabetes 677 (14%) 
Heart Disease 642 (14%) 
Depression 625 (13%) 
Lung Disease 323 (7%) 
Cancer 221 (5%) 
Stroke 178 (4%) 
Rheumatoid Arthritis 163 (3%) 
Stomach Disease 154 (3%) 
Blood Disease 119 (3%) 
Kidney Disease 114 (2%) 
Other 725 (15%) 
Number of comorbidities; Mean (SD) 1.2 (1.2%) 
Age 
Under 20 17 (0%) 
20–29 104 (2%) 
30–39 226 (5%) 
40–44 175 (4%) 
45–49 316 (7%) 
50–54 453 (10%) 
55–59 601 (13%) 
60–64 719 (15%) 
65–69 716 (15%) 
70–74 633 (14%) 
75–79 412 (9%) 
80–84 191 (4%) 
85+ 82 (2%) 
Gender 
Male 1534 (33%) 





New Zealand European/Pākehā 3365 (72%) 
Māori 907 (19%) 
Pasifika 435 (9%) 
Asian 183 (4%) 
Other 54 (1%) 
Duration of Condition  
Less Than Three Months 139 (3%) 
Three to Twelve Months 949 (20%) 
Twelve to Twenty-Four Months 819 (17%) 
Two to Five Years 1194 (25%) 
More Than Five Years 1640 (35%) 
Diagnosis 
OA 3670 (77%) 
Knee/hip pain, no OA diagnosis 252 (5%) 
Back pain 479 (10%) 
Gout 55 (1%) 
Other 292 (6%) 
Referral Source 
GP 3180 (67%) 
Māori/Pasifika Health Provider 133 (3%) 
Nurse 113 (2%) 
Pharmacist 23 (0%) 
Public Hospital 252 (5%) 
Public (Other) 186 (4%) 
Self-referral 663 (14%) 
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2.2. Health outcomes 
Data on 12 quantitative health outcome measures were collected by MAPs at four timepoints: 
baseline (Time 1); discharge (Time 2); +3 months follow-up post-discharge (Time 3); and +12 
months follow-up post-discharge (Time 4). The intent was to identify changes in physical, 
functional, and psychological components of participants’ MSK conditions (see Appendix E page 
85 for methodological and demographic details). These measures are summarised in Table 6.24 
Table 6: Overview of health outcome measures used in the MAP 
Number Full name of measure Acronym Description of what measure assesses 
1 Timed Up and Go Test25 TU&G Changes in mobility and function for participants 
with lower limb and back conditions. 
2 The Lower Extremity 
Function Scale26 
LEFS Changes in function for participants with lower limb 
conditions. 
3 The Oxford Hip Score27 OHS Changes in pain function for participants with 
osteoarthritis of the hip. 
4 The Oxford Knee Score28 OKS Changes in pain function for participants with 
osteoarthritis of the knee. 
5 The QuickDASH Outcome 
Measure29 
QuickDASH Changes in function for participants with hand, arm 
and shoulder conditions. 
6 The Roland-Morris 
Disability Questionnaire30 
RMDQ Disability related to back pain. 
7 The Numeric Pain Rating 
Scale31 
NPRS Current pain ratings corresponding to current, best 
and worst pain. 
 
24 See Appendix E for MAP participants’ average or mean scores on all 12 health outcome measures across 
each timepoint (Times 1 – 4). 
25 Podsiadlo, D., & Richardson, S. (1991). The timed “Up & Go”: a test of basic functional mobility for frail 
elderly persons. Journal of the American Geriatrics Society,39(2), 142-148. 
26 Binkley, J. M., Stratford, P. W., Lott, S. A., Riddle, D. L., & North American Orthopaedic Rehabilitation 
Research Network (1999). The Lower Extremity Functional Scale (LEFS): Scale development, measurement 
properties, and clinical application. Physical Therapy, 79(4), 371-383. 
27 Dawson, J., Fitzpatrick, R., Carr, A., & Murray, D. (1996). Questionnaire on the perceptions of patients 
about total hip replacement. Journal of Bone and Joint Surgery, 78(B),185-190. 
28 Dawson, J., Fitzpatrick, R., Murray, D. & Carr, A. (1998). Questionnaire on the perceptions of patients about 
total knee replacement. Journal of Bone and Joint Surgery; 80(B), 63-69. 
29 Beaton, D.E., Wright, J.G., Katz, J.N., and the Upper Extremity Collaborative Group (2005). Development of 
the QuickDASH: Comparison of three item-reduction approaches. Journal of Bone and Joint Surgery 87A(5), 
1038-1046. 
30 Roland, M., & Morris, R. A. (1983). Study of the natural history of low back pain: Part 1. Development of a 
reliable and sensitive measure of disability in low-back pain. Spine, 8, 141–144. 
31 McCaffery, M., & Pasero, C. (1999). 0–10 Numeric Pain Rating Scale. Pain: Clinical manual, 2nd Edition. St. 
Louis, MO: Mosby. 
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Number Full name of measure Acronym Description of what measure assesses 
8 Vernon Mior Neck 
Disability Index32 
NDI Assesses degree to which neck pain has affected 
participants ability to manage in everyday life 




SF-12 PSC Physical health component summary measure of the 
SF-12 Health Survey 




SF-12 MSC Mental health component summary measure of the 
SF-12 Health Survey 
11 The SF-6D Health Utility 
Value36 
SF-6D Uses the SF-12 to estimate a single index measure 
for health using general population values 
12 Stanford Self-Efficacy 
Scale37 
SSES Self-efficacy for managing chronic disease 
Analysis of these health outcome measures found statistically significant improvements between 
the time of participants’ entry into their MAP (baseline or Time 1) and all other timepoints for all 
outcome measures. Further, the degree of improvements in participants’ scores was reasonably 
consistent across timepoints. Table 7 presents changes in MAP participants’ scores between Time 
1 and the three other timepoints (Times 2 through 4).  
Table 7: Change in health outcomes relative to baseline (Score and 95% CI) 







Numerical Pain Rating Scale -1.1 (-1.1 to -1.0) -1.0 (-1.1 to -1.0) -1.0 (-1.1 to -0.9) 
Timed Up and Go Test -1.7 (-1.8 to -1.5) -2.1 (-2.4 to -1.8) -2.1 (-2.4 to -1.7) 
 
32 Vernon, H. & Mior, S. (1991). The Neck Disability Index: A study of reliability and validity. Journal of 
Manipulative and Physiological Therapeutics. 14, 409-415. 
33 Ware, J.E., Kosinski, M., & Keller, S.D. (1996) A 12-Item Short-Form Health Survey: Construction of scales 
and preliminary tests of reliability and validity. Medical Care; 34(3), 220–233. 
34 Ibid. 
35 Tools such as the mental health component of the SF-12 are not used for diagnostic purposes or to 
measure specific mental health conditions. In this instance, the tool measures the high-level impact of 
emotional concerns on participants’ functioning. 
36 Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from 
the SF-36. Journal of Health Economics, 21(2), 271–292. 
37 Lorig, K., Chastain, R. L., Ung, E., Shoor, S., & Holman, H. R. (1989). Development and evaluation of a scale 
to measure perceived self‐efficacy in people with arthritis. Arthritis & Rheumatism: Official Journal of the 
American College of Rheumatology, 32(1), 37-44. 
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SF-12 Physical Health Score ^ 4.1 (3.7 to 4.4) 3.4 (3.1 to 3.7) 
SF-12 Mental Health Score ^ 1.6 (1.2 to 1.9) 1.0 (0.6 to 1.4) 
SF-6D Health Utility Value ^ 0.05 (0.04 to 0.05) 0.04 (0.03 to 0.04) 
Stanford Self-Efficacy Score 0.9 (0.9 to 1.0) 0.8 (0.8 to 0.9) 0.7 (0.7 to 0.8) 
Lower Extremity Function Scale 7.7 (6.3 to 9.0) 6.3 (4.8 to 7.7) 6.3 (4.9 to 7.8) 
Oxford Hip Score 4.4 (3.7 to 5.1) 3.5 (2.8 to 4.2) 3.2 (2.5 to 4.0) 
Oxford Knee Score 4.8 (4.4 to 5.2) 4.8 (4.4 to 5.3) 4.5 (4.1 to 5.0) 
QuickDASH Score -8.0 (-12.8 to -3.1) -8.3 (-13.3 to -3.3) -7.3 (-12.4 to -2.2) 
Roland Morris Disability Questionnaire -3.2 (-3.5 to -2.9) -3.0 (-3.3 to -2.6) -3.1 (-3.5 to -2.8) 
Vernon-Moir Index -5.7 (-7.8 to -3.5) -6.1 (-8.9 to -3.3) -6.1 (-9.5 to -2.7) 
Note: ^ indicates no data collected; 95% confidence intervals are presented in brackets; Data for the Timed 
Up and Go Test were only collected for 607 participants (5 programmes) at Time 3 and 288 participants (5 
programmes) at Time 4. 
Demographically, younger participants and women showed greater improvement across these 
measures. Subsequent sections outline other key demographic differences of interest across 
specific MAP outcome measures.38 
2.2.1. MAP participants’ general health status, pain, functional status, self-confidence and 
ability to self-manage their condition 
Change in behaviours 
As a proxy indicator, quantitative findings regarding participant BMI suggest that participants 
may be modifying their behaviours (e.g., exercise or dietary habits) to improve their health 
outcomes.39 
There was a reduction in cohort BMI from Time 1 to Time 2. Among the 3,450 participants who 
had BMI data collected at both Time 1 and Time 2, with an average reduction of 0.16 kg/m2 (95 
percent CI: 0.12 to 0.21).  
All but one programme (Programme 13) had reductions in average cohort BMI between Time 1 
and Time 2 (Error! Reference source not found.), and seven of these were statistically s
ignificant. Further, reductions in BMI were maintained or improved at Time 3, with an average 
 
38 Other key demographic variables analysed include age, comorbidities, and condition severity.  
39 These proxy findings should be interpreted with caution, as weight reduction cannot be directly 
attributed to participants’ engagement in the MAP. 
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reduction of 0.34 kg/m2 (95 percent CI: 0.28 to 0.39) and Time 4 (0.42; 95 percent CI: 0.36 to 
0.47). All programmes with available data had reductions in BMI at both Time 3 and Time 4. 
















Note: Negative values signify reduced BMI; error bars show mean and 95% confidence intervals; * indicates a 
statistically significant change. The green bar shows change in BMI from Time 1 to Time 2, the orange bar 
change from Time 1 to Time 3, and the lavendar bar change from Time 1 to Time 4. 
Evidence from the MAP consumer survey supports these findings regarding health-related 
behaviour changes.40 Across all those who responded, the majority (86 percent) reported learning 
about exercise; with others learning about: 
• back, knee, or hip pain (72 percent); 
• how to manage their condition (69 percent); 
• arthritis (66 percent); 
• how to manage their pain (57 percent); 
• treatments for their condition (45 percent); 
• diet (36 percent) and weight management (32 percent).  
A small proportion of survey participants learnt about quitting smoking (3.6 percent) and 3.5 
percent said they did not learn anything.  
 
40 See Appendices E and F for further information about the MAP consumer survey. 
 
Programme 1 (N = 162/6/22) -0.00/--/-0.81* 
Programme 2 (N = 285/120/96)      -0.14*/-0.46*/-0.45* 
Programme 3 (N = 62/1/4) -0.04/--/--  
Programme 4 (N = 70/61/42) -0.42*/-0.15/-0.31 
Programme 5 (N = 285/275/267) -0.05/-0.17/-0.19 
Programme 6 (N = 122/65/47) -0.14/-0.61*/-0.68* 
Programme 7 (N = 169/154/138) -0.18*/-0.31*/0.54* 
Programme 8 (N = 257/249/240) -0.33*/-0.58*/-0.73* 
Programme 9 (N = 191/36/12) -0.80*/-0.88*/-1.20* 
Programme 10 (N = 149/139/133) -0.03/-0.28*/-0.10 
Programme 11 (N = 262/317/310) -0.08/-0.09/-0.16 
Programme 12 (N = 371/197/101) -0.14*/-0.50*/-0/91* 
Programme 13 (N = 97/12/4) 0/00/-1.73*/-- 
Programme 14 (N = 193/175/149) -0.12?-0.28/-0.32* 
Programme 15 (N = 312/284/285) -0.22/-0.41*/-0.53* 
Programme 16 (N = 245/240/234) -0.06/-0.16/-0.17 
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Table 8: Self-reported learnings from MAP (counts and percentages) 
 What did you learn about in your MAP Value 
Arthritis 668 (65.6%) 
Back knee or hip pain 730 (71.6%) 
How to manage my condition 705 (69.2%) 
Treatments for my condition 462 (45.3%) 
How to manage my pain 578 (56.7%) 
Exercise 877 (86.1%) 
Quitting smoking 37 (3.6%) 
Improving my diet 369 (36.2%) 
Managing my weight 324 (31.8%) 
I didn't learn anything 36 (3.5%) 
There were no significant differences in age and gender sub-group analyses for survey 
respondents who reported learning how to manage their condition and how to treat their 
condition.  
Some statistically significant differences were found regarding referral type and ethnicity. Those 
survey respondents who attended group sessions or mixed individual/group MAP sessions 
reported a 2.5 times greater improvement in knowledge about improving their diet than those 
who attended individual sessions (RR = .35, χ2 = 18.14, p < .001).  
Respondents identifying as Māori were 1.9 times more likely to report learning how to manage 
their weight than non-Māori (RR = .54, χ2 = 5.45, p = .02) and 1.6 times more for those who had 
self-referred than referred by a GP (RR = 1.76, χ2 = 9.25, p = .002). 
Reduction in pain  
Changes in pain were measured by the Numerical Pain Rating Scale (NPRS). There was a 
significant reduction in pain between Time 1 and Time 2 of 1.07 points (95 percent CI: 1.00 to 
1.14). All 17 MAPs had reductions in average reported pain scores at Time 2, with statistically 
significant reductions in all but two (Figure 2). 
The reductions in pain were maintained through follow-ups at Time 3 (1.03; 95 percent CI: 0.95 
to 1.10) and Time 4 (0.99; 95 percent CI: 0.92 to 1.07). All programmes at Time 3 and all but one 
programme (Programme 6) at Time 4 had reductions in average pain, most of which were 
statistically significant.  
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Figure 2: Change in NPRS scores between Time 1 and Times 2 through 4, by programme 
 
Mobility and functionality  
Improvements in mobility and functionality health outcomes were found across the MAP 
participant cohort at all follow-up points using the following assessments: Timed Up and Go 
(TU&G), the Lower Extremity Function Scale (LEFS), the Oxford Hip and Knee Scores (the OHS 
and OKS), the Disabilities of the Arm, Hand, and Shoulder (QuickDASH) questionnaire, the Roland-
Morris Disability Questionnaire (RMDQ), and the Vernon-Mior Neck Disability Index (NDI). 
Programme-level changes for each of these outcome measures are outlined below.41 
  
 
41 The QuickDASH is excluded due to small sample sizes. A total of 24 participants in two programmes 
completed the QuickDASH at both Times 1 and 2 with an average improved score of 11.0 points (95% CI: 
1.4 to 20.5).  
 
Programme 1 (N = 176/133/135)  -0.42*/-0.31/-0.33 
Programme 2 (N = 297/224/207) -0.09/-0.46*/-0.48* 
Programme 3 (N = 62/49/52) -0.68*/-0.10/-0.02 
Programme 4 (N = 91/79/60) -0.47*/-0.30/-0.31 
Programme 5 (N = 291/283/265) -0.91*/-1.18*/-1.47* 
Programme 6 (N = 127/97/67) -0.23/-0.10/0.66* 
Programme 7 (N = 170/154/138) -1.62*/-1.80*/-1.87* 
Programme 8 (N = 237/250/241) -0.86*/-0.59*/-0.27 
Programme 9 (N = 190/38/7) -1.60*/-1.39*/-- 
Programme 10 (N = 143/143/134)  -1.15*/-1.81*/-1.70* 
Programme 11 (N = 262/318/312) -1.95*/-1.03*/-1.04* 
Programme 12 (N = 419/367/295) -1.29*/-1.05*/-0.77* 
Programme 13 (N = 97/84/64) -1.21*/-1.34*/-0.92* 
Programme 14 (N = 199/189/187) -0.87*/-1.02*/-0.68* 
Programme 15 (N = 315/289/298) -1.24*/-1.49*/-1.55* 
Programme 16 (N = 246/250/236) -1.20*/-1.29*/-1.63* 
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Timed Up and GO (TU&G) 
The average improvement in the TU&G was 1.7s (95% CI: 1.5 to 1.8) at Time 2. All MAPs had 
improvements in TU&G times, with statistically significant changes in 15 programmes. Figure 3 
summarises the mean change in TU&G scores between Times 1 and 2). The TU&G test was not 
collected at Times 3 and 4. 
 
The Lower Extremity Function Scale (LEFS) 
Average improvements in the LEFS were 7.7 points (95 percent CI: 6.3 to 9.0) at Time 2, 6.3 points 
(95 percent CI: 4.8 to 7.7), and 6.3 points (95 percent CI: 4.9 to 7.8) at Time 4. As condition-specific 
outcome measures were collected only from participants with certain conditions, not all 
programmes contributed data for this measure (or the other condition-specific measures 
presented below). Eight programmes contributed LEFS data at Time 2, all but one which showed 
statistically significant improvements in average scores (Error! Reference source not found.4). S
even programmes contributed data at both Time 3 and Time 4; four had significant improvements 
at Time 3 and five at Time 4.  
  
Figure 3: Change in TU&G scores between Time 1 and Time 2, by programme  
Programme 1 (N = 171)  -0.51 
Programme 2 (N = 297) -2.03* 
Programme 3 (N = 59) -2.27* 
Programme 4 (N = 48) -0.68 
Programme 5 (N = 294) -1.33* 
Programme 6 (N = 105) -2.47* 
Programme 7 (N = 170) -2.12* 
Programme 8 (N = 257) -1.15* 
Programme 9 (N = 170) -1.28* 
Programme 10 (N = 123)  --1.78* 
Programme 11 (N = 235) -2.55* 
Programme 12 (N = 417) -1.96* 
Programme 13 (N = 97) -1.94* 
Programme 14 (N = 198) --1.37* 
Programme 15 (N = 308) -2.13* 
Programme 16 (N = 227) -1.47* 




Note: Smaller samples for which this measure was collected means all other MAPs were excluded from this 
analysis (see Appendix E for details).  
The Oxford Hip Score (OHS) 
Average improvements in the OHS were 4.4 points (95 percent CI: 3.7 to 5.1) at Time 2, 3.5 points 
(95 percent CI: 2.8 to 4.2) at Time 3, and 3.2 points (95 percent CI: 2.5 to 4.0) at Time 4.  
Thirteen programmes contributed OHS data at Time 2, all of which showed improvements in 
average scores, and all but two had statistically significant improvements (Error! Reference s
ource not found.). Eleven programmes contributed data at both Time 3 and Time 4; all but one 
had improvements at both time points. One programme had statistically significant worsening in 
OHS scores at Time 4. 
Figure 4: Change in LEFS scores between Time 1 and Times 2 through 4, by programme 
Figure 5: Change in OHS scores between Time 1 and Times 2 through 4, by programme 
 
Programme 2 (N = 59/51/45) 9.46*/3.78/5.38* 
Programme 4 (N = 22/19/14) 6.59*/4.00/5.50 
Programme 5 (N = 61/59/54) 9.80*/10.56*/9.44* 
Programme 7 (N = 14/13/11) 7.71*/5.85/4.55 
Programme 9 (N = 30/4/1) -0.83/--/-- 
Programme 11 (N = 35/49/49) 12.43*/7.35*/6.31* 
Programme 14 (N = 12/12/12) 8.92*/11.08*/11.08* 
Programme 16 (N = 257/245/252) 7.33*/5.78*/5.93* 
Programme 17 (N = 2/0/0) --/--/-- 
 
Programme 2 (N = 42/33/30) 1.40/4.61*/3.10 
Programme 3 (N = 10/8/9) 6.10*/--/-- 
Programme 4 (N = 23/18/14) 3.57*/4.17/4.00 
Programme 5 (N = 50/47/41) 5.66*/5.15*/8.68* 
Programme 6 (N = 53/45/34) 1.60/-0.71/4.71* 
Programme 7 (N = 19/18/16) 5.47*/4.39*/6.13* 
Programme 8 (N = 102/101/94) 3.45*/2.01*/0.47 
Programme 9 (N = 21/7/1) 4.81*/--/-- 
Programme 11 (N = 45/50/48) 7.09*/3.86*/3.15* 
Programme 12 (N = 138/112/84) 5.49*/5.29*/4.18* 
Programme 13 (N = 28/24/21) 3.43*/2.08/1.33 
Programme 14 (N = 60/57/59) 6.05*/4.25*/5.07* 
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Note: Higher values signify better health outcomes; error bars show 95% confidence intervals; * indicates a 
statistically significant change. 
The Oxford Knee Score (OKS) 
Average improvements in the OKS were 4.8 points (95 percent CI: 4.4 to 5.2) at Time 2, 4.8 points 
(95 percent CI: 4.4 to 5.3) at Time 3, and 4.5 points (95 percent CI: 4.1 to 5.0) at Time 4.  
Of the fourteen programmes contributing data on OKS outcomes at Time 2, all but one showed 
statistically significant improvements (Error! Reference source not found.6).  
Thirteen programmes contributed OKS data at each of Times 3 and 4; all showed improvements 
in average scores at both time points. 
Figure 6: Change in OKS scores between Time 1 and Times 2 through 4, by programme 
 
Note: Higher values signify better health outcomes; error bars show 95% confidence intervals; * indicates a 
statistically significant change. 
The Disabilities of the Arm, Hand, and Shoulder (QuickDASH) questionnaire 
Average improvements in the QuickDASH were 8.0 points (95 percent CI: 3.1 to 12.8) at Time 2, 
8.3 points (95 percent CI: 3.3 to 13.3) at Time 3, and 7.3 points (95 percent CI: 2.2 to 12.4) at Time 
4.  
Only two programmes contributed sufficient QuickDASH data at each follow-up point. Both had 
improvements at all time points; one had statistically significant improvements (Error! R




Programme 2 (N = 197/141/131) 2.24*/3.09*/1.94* 
Programme 3 (N = 12/20/19) 4.86/-0.30/-2.16* 
Programme 4 (N = 46/42/31) 3.30*/3.88*/1.78 
Programme 5 (N = 114/107/101) 6.25*/6.21*/6.69* 
Programme 6 (N = 74/53/34) 2.42*/0.96/-0.12 
Programme 7 (N = 26/24/23) 4.96*/3.13*/3.91* 
Programme 8 (N = 155/149/147) 5.39*/6.32*/5.63* 
Programme 9 (N = 45/7/8) 3.42*/-=/-- 
Programme 10 (N = 143/143/132)  2.41*/3.76*/3.78* 
Programme 11 (N = 87/101/99) 6.89*/5.05*/4.58* 
Programme 12 (N = 283/255/211) 5.91*/5.52*/5.14* 
Programme 13 (N = 69/60/43) 4.64*/5.48*/8.74* 
Programme 14 (N = 127/120/116) 5.50*/5.38*/5.52* 




Note: Lower values signify less disability; error bars show 95% confidence intervals; * indicates a statistically 
significant change. 
The Roland-Morris Low Back Pain and Disability Questionnaire (RMDQ) 
Average improvements in the RMDQ were 3.2 points (95 percent CI: 2.9 to 3.5) at Time 2, 3.0 
points (95 percent CI: 2.6 to 3.3) at Time 3, and 3.1 points (95 percent CI: 2.8 to 3.5) at Time 4.  
Eight programmes contributed RMDQ data at Time 2, all of which showed statistically significant 
improvements in average scores (Error! Reference source not found.).  
Eight programmes contributed data at Time 3 and seven at Time 4; all had improvements and all 
but two had statistically significant improvements at both time points.  
Note: Lower values signify less disability; error bars show 95% confidence intervals; * indicates a statistically 
significant change. 
The Vernon-Mior Neck Disability Index (NDI) 
Average improvements in the NDI were 5.7 points (95 percent CI: 3.5 to 7.8) at Time 2 and 6.1 
points (95 percent CI: 3.3 to 8.9) at Time 3.  
There were insufficient data for analysis at Time 4. Only two programmes contributed NDI data, 
both of which showed statistically significant improvements in average scores at Time 2 (Error! R
eference source not found.). Neither programme had sufficient data for analysis at later time 
points. 
Figure 7: Change in QuickDASH scores between Time 1 and Times 2 through 4, by programme 
Figure 8: Change in RMDQ scores between Time 1 and Times 2 through 4, by programme 
 
Programme 1 (N = 1/1/1) --/--/-- 
Programme 7 (N = 18/17/17) -2.67/-7.88/-8.29 
Programme 9 (N = 2/0/0) --/--/-- 
Programme 11 (N = 34/35/34) -12.21*/-10.46*/-9.94* 
 
 
Programme 1 (N = 175/133/135) -2.85*/-2.52*/-2.52* 
Programme 3 (N = 28/21/23) -2.71*/-1.43/-1.26 
Programme 5 (N = 72/70/69) -3.10*/-3.20*/-3.88* 
Programme 7 (N = 80/73/63) -2.70*/-3.00*/-- 
Programme 9 (N = 48/10/2) -3.62*/-3.00/-- 
Programme 11 (N = 59/82/80) -5.37*/-4.93*/-5.09* 
Programme 15 (N = 58/44/46) -4.00*/-3.91*/-2.00* 
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Note: Lower values signify less disability; error bars show 95% confidence intervals; * indicates a statistically 
significant change. 
Confidence to self-manage conditions 
There were statistically significant improvements in participants’ perceived ability and 
confidence to self-manage their conditions, as measured by the Stanford Self-Efficacy Scale (SSES). 
Scores improved by an average of 0.93 points at Time 2 (95 percent CI: 0.86 to 1.00), 0.83 points 
at Time 3 (95 percent CI: 0.76 to 0.90) and 0.74 points at Time 4 (95 percent CI: 0.67 to 0.82). 
Improvements were seen in all programmes at Time 2, and all but one at Times 3 and 4 (Error! R
eference source not found.). There were similar results for the proportion of participants rating 
their confidence to self-manage their condition at a score of 7 out of 10 or higher, indicating a high 
level of self-efficacy. 
Figure 10: Change in SSES scores between Time 1 and Times 2 through 4, by programme 
Figure 9: Change in NDI scores between Time 1 and Time 2, by programme 
 
 
Programme 7 (N = 13/9/8) -4.92*/--/-- 
Programme 9 (N = 10/3/0) -6.20*/--/-- 
 
 
Programme 1 (N = 176/133/135)  0.75*/1.03*/0.78* 
Programme 2 (N = 297/224/207) 0.27*/0.17/0.04 
Programme 3 (N = 62/49/52) 0.77*/0.10/0.25 
Programme 4 (N = 91/79/60) 0.61*/0.63*/0.73* 
Programme 5 (N = 291/283/265) 1.13*/1.46*/1.59* 
Programme 6 (N = 127/97/67) 0.43*/0.15/-0.32 
Programme 7 (N = 170/154/138) 1.05*/0.83*/0.83* 
Programme 8 (N = 237/250/241) 0.80*/0.40*/0.00 
Programme 9 (N = 190/38/7) 1.48*/1.60*/-- 
Programme 10 (N = 143/143/134)  0.65*/0.60*/0.13 
Programme 11 (N = 262/318/312) 1.96*/1.82*/1.99* 
Programme 12 (N = 419/367/295) 0.70*/0.72*/0.49* 
Programme 13 (N = 97/84/64) 0.59*/-0.08/0.23 
Programme 14 (N = 199/189/187) 0.80*/0.72*/0.77* 
Programme 15 (N = 315/289/298) 1.05*/0.89*/0.58* 
Programme 16 (N = 246/250/236) 1.04*/1.01*/1.13* 




Note: Higher values signify greater improvements in self-efficacy; error bars show 95% confidence intervals; 
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Positive indicators of enhanced self-efficacy and confidence were echoed by MAP consumer 
survey respondents and virtual MAP provider focus groups. Over two-thirds (69 percent) of the 
MAP survey respondents reported learning how to manage their condition.42 Further, MAP 
providers suggested that individual-based sessions that offered more privacy and ability to tailor 
personal programmes may have helped bolster participants’ sense of independence and 
confidence to self-manage their conditions and implement their care plans. 
MAP clients’ general health and wellbeing 
The SF-12 survey of general health-related quality of life was collected as part of the MAP 
participant data at Times 1, 3, and 4.  
There were statistically significant improvements in all general health measures at Times 3 and 
4. SF-12 Physical Component Summary (PCS) scores improved by an average of 4.1 points (95 
percent CI: 3.7 to 4.4) at Time 3 and 3.4 points (95 percent CI: 3.1 to 3.7) at Time 4.  
SF-12 Mental Component Summary (MCS) scores improved by an average of 1.6 points (95 
percent CI: 1.2 to 1.9) at Time 3 and 1.0 points (95 percent CI: 0.6 to 1.4) at Time 4.  
SF-6D health utility values improved by an average of 0.05 (95 percent CI: 0.05 to 0.05) at Time 3 
and 0.04 (95 percent CI: 0.035 to 0.044) at Time 4. 
All programmes had an improvement in PCS scores at Time 3, and all but two had improvements 
in PCS scores at Time 4 (Error! Reference source not found.). Most programme-level i
mprovements were statistically significant at both time points. One programme had a statistically 
significant worsening in PCS scores at Time 4. 
 
42 No sub-group differences were found for age, gender, ethnicity or referral type. 
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Note: higher values signify greater improvements in general physical health; error bars show 95% confidence 
intervals; and * indicates a statistically significant change. 
Most programmes had improvements in average MCS scores at both Time 3 and Time 4 (Error! R
eference source not found.). Seven programmes had statistically significant improvements at 
Time 3, and five had statistically significant improvements at Time 4. One programme at each of 
Times 3 and 4 had a statistically significant worsening of MCS scores. 
Figure 11: Change in PCS scores between Time 1 and Times 3 and 4, by programme  
Programme 1 (N = 133/135)  4.77*/4.51* 
Programme 2 (N = 224/207) 3.09*/1.87* 
Programme 3 (N = 50/52) 0.35/0.92 
Programme 4 (N = 79/60) 4.53*/2.62* 
Programme 5 (N = 283/265) 7.09*/7.28* 
Programme 6 (N = 98/66) 1.32/-2.38* 
Programme 7 (N = 154/138) 5.90*/5.35* 
Programme 8 (N = 250/241) 2.70*/1.60* 
Programme 9 (N = 36/7) 4.34*/-- 
Programme 10 (N = 140/130)  4.23*/-1.47 
Programme 11 (N = 318/312) 4.89*/4.59* 
Programme 12 (N = 367/295) 4.54*/3.42* 
Programme 13 (N = 83/63) 2.87*/3.37* 
Programme 14 (N = 189/187) 4.39*/5.47* 
Programme 15 (N = 259/265) 4.63*/4.26* 
Programme 16 (N = 202/189) 0.32/0.57 
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Note: higher values signify greater improvements in general mental health; error bars show 95% confidence 
intervals; and * indicates a statistically significant change. 
All but two programmes at each of Times 3 and 4 had improvements in average SF-6D health 
utility values (Figure 13). Most programme-level improvements were statistically significant at 









Programme 1 (N = 133/135)  2.57*/0.85 
Programme 2 (N = 224/207) 1.94*/1.31 
Programme 3 (N = 50/52) 0.56/2.28 
Programme 4 (N = 79/60) 1.28/1.99 
Programme 5 (N = 283/265) 3.10*/3.18* 
Programme 6 (N = 98/66) 3.18*/-1.31 
Programme 7 (N = 154/138) 0.90/0.42 
Programme 8 (N = 250/241) 1.08/-0.03 
Programme 9 (N = 36/7) 10.23*/-- 
Programme 10 (N = 140/130)  -1.53/-5.87* 
Programme 11 (N = 318/312) 3.08*/4.59* 
Programme 12 (N = 367/295) 1.08/-0.34 
Programme 13 (N = 83/63) -0.45/-0.15 
Programme 14 (N = 189/187) 1.28/2.18* 
Programme 15 (N = 259/265) 2.49*/1.93* 
Programme 16 (N = 202/189) -1.00/-0.45 
Programme 17 (N = 153/138) 0.74/1.58 
 
Figure 12: Change in MCS scores between Time 1 and Times 3 and 4, by programme 
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Figure 13: Change in SF-6D values between Time 1 and Times 3 and 4, by programme 
 
Note: higher values signify greater improvements in health-related quality of life; error bars show 95% 
confidence intervals; and * indicates a statistically significant change. 
Consumer survey findings generally supported the above findings related to general health and 
wellbeing. The majority of respondents reported ‘some’ or ‘lots of’ improvements in their overall 
health (N = 759, 86.7 percent) compared to 13.3 percent who said their overall health had not 
improved. Further, sub-group analyses found that respondents who identified as Māori were 3.6 
times more likely to report health improvements than non-Māori (RR = .28, χ2 = 4.36, p = .04). 
Survey respondents also reported improvements in their overall quality of life (N = 765, 89.4 
percent), with female participants 1.8 times more likely to report improved life quality than males 
(RR = .55, χ2 = 6.30, p = .012). 
Secondary healthcare services  
Secondary healthcare services include specialist level care, often based in a hospital setting. For 
MSK conditions, this may include services provided by orthopaedic surgeons or rheumatologists. 
Quantitative and qualitative data were collected to determine the extent to which involvement in 
the MAP reduces clients’ need for secondary healthcare services. Findings were favourable. MAP 
participant data analyses found statistically significant reductions in: 
• specialist referrals, with an average of 0.08 fewer referrals in Time 2 compared to Time 1 
(95 percent CI: 0.06 to 0.10); 
• specialist visits (0.04 fewer; 95% CI: 0.01 to 0.07); and 
• emergency department visits (0.01 fewer; 95% CI: 0.002 to 0.03). 
Programme 1 (N = 133/135)  0.074*/0.055* 
Programme 2 (N = 224/207) 0.036*/0.026* 
Programme 3 (N = 50/52) -0.008/0.016 
Programme 4 (N = 79/60) 0.042*/0.026 
Programme 5 (N = 283/265) 0.090*/0.094* 
Programme 6 (N = 98/66) -0.021/-0.036* 
Programme 7 (N = 154/138) 0.056*/0.041* 
Programme 8 (N = 250/241) 0.035*/0.022* 
Programme 9 (N = 36/7) 0.159*/-- 
Programme 10 (N = 140/130)  0.024*/-0.071* 
Programme 11 (N = 318/312) 0.062*/0.065* 
Programme 12 (N = 367/295) 0.045*/0.029* 
Programme 13 (N = 83/63) 0.044*/0.037* 
Programme 14 (N = 189/187) 0.048*/0.073* 
Programme 15 (N = 259/265) 0.074*/0.064* 
Programme 16 (N = 202/189) 0.013/0.003 
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There was no significant change in the number of hospital admissions in Time 2 compared to Time 
1.43  
Reductions in secondary healthcare utilisation were largely sustained through Times 3 and 4. 
Participants reported an average of 0.12 fewer specialist referrals (95 percent CI: 0.10 to 0.14) at 
Time 3 and 0.11 fewer at Time 4 (95 percent CI: 0.08 to 0.13). There were also 0.02 fewer reports 
of emergency department visits (95 percent CI: 0.004 to 0.03) at Time 3 and 0.03 fewer at Time 4 
(95 percent CI: 0.01 to 0.04). Last, there was a small but statistically significant increase in the 
reported number of hospital admissions at Time 4 (0.01; 95 percent CI: 0.0001 to 0.02). 
Most programmes had reductions in the number of specialist referrals, specialist visits and 
emergency department visits reported at all follow-up time points, but few changes were found 
to be statistically significant due to the small number of participants reporting any secondary 
healthcare utilisation. 
See Section  for further information on MAP’s likely impact on healthcare service utilisation. 
2.2.2. Health outcomes summary 
Overall evaluation findings indicate that participation in the MAP (across either all or most MAPs) 
contributed to: 
• a maintained reduction in BMI; 
• significant improvements in health-related behaviour changes; 
• significant reductions in pain and improvements in mobility and functionality; 
• significant improvements in participants’ perceived ability and confidence to self-
manage their conditions; 
• significant improvements in general health and wellbeing; and 














In the context of this evaluation, the criterion of “reach” is defined as the extent to which the MAPs 
achieved their contracted participant enrolment volumes and completion rates. 
Section 0 discusses the extent to which the MAP reduced disparities in access and health outcomes 
for priority groups experiencing MSK conditions (Māori, Pasifika, and those living in areas of 
higher deprivation). 
Participant enrolment rates  
The figure below displays actual enrolments against contracted enrolment numbers for each MAP 
provider. Eleven of the 17 providers achieved at least 80 percent of their enrolment target; two 
achieved less than 50 percent of their target. 
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Completion rates  
Across all programmes, 78 percent of participants completed their programme to the point of 
discharge (Time 2). Nine programmes achieved completion rates of at least 80 percent (Figure 
15).44  
 
2.3.1. Reasons for non-completion and mitigation strategies 
MAP providers and stakeholders provided insights into factors that contributed to non-
completion rates for their programmes. ‘Inappropriate referrals’ were a key reason for 
participants not completing the programme. Examples of inappropriate referrals included: 
• participants experiencing more severe OA than what was intended by MAP’s early-
intervention philosophy, who found the programme difficult to undertake and/or 
continue to participate in; 
• participants experiencing more severe OA who were on the waitlist for surgery and who 
viewed the MAP as a ‘tick box’ item pre-surgery, which may have demotivated them to 
complete the programme or take it seriously; 
• participants who had not really ‘bought into’ the self-management philosophy of the MAP 
or who lacked confidence in their ability to improve their self-management skills; and 
 
44 Time points 3 and 4 are data collection points at which participant monitoring data was collected to 
inform the evaluation.  
Figure 15: MAP completion rates, by time point and programme 
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• participants with limited computer literacy who had been referred onto the programme, 
which made completing virtual/online components of MAPs challenging or led to them 
withdrawing. 
Other barriers for completion included:  
• participants with comorbidities, such as pre-existing physical and/or mental health 
issues; 
• practical issues such as participants not having transport to the programme, or not having 
childcare; and 
• participants not understanding or buying into the MAP’s self-management approach to 
MSK conditions, having previously experienced clinician-led management of their 
conditions. 
Providers that used group, rather than individual, sessions had the strongest completion rates – 
all nine providers that reached 80 percent completion rates used a group format. Providers also 
stated it was important to build rapport with participants to enhance buy-in, set expectations 
around attendance, and offer an easy-to-follow, structured programme. 
Programme length did not impact on completion rates: five of the MAPs that reached 80 percent 
completion were longer than 11 weeks and four were shorter than 11 weeks.  
2.3.2. Reach summary  
Evaluation findings about the reach of the MAP indicate that: 
• most providers achieved at least 80 percent of their enrolment target; 
• nine providers achieved completion rates (discharge at Time 2) of at least 80 percent; 
• factors contributing to non-completion included inappropriate referrals; participants 
with comorbidities and complex needs; and participants not understanding or buying 
into the self-management aspects of the MAP; and 
• providers’ strategies to enhance reach and mitigate non-completion included that 
offering group sessions, building rapport with participants to enhance buy-in, setting 
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2.4. Reducing disparities 
The MAP aimed to reduce disparities in access and health outcomes and work towards achieving 
equity by engaging Māori, Pasifika and those living in areas of high deprivation. 
During the contracting process, the Ministry prioritised MAP providers with a strong focus on 
delivery to priority population groups. All MAPs provided plans to the Ministry outlining how they 
would address health disparities in these priority groups.45,46,47 
The following section details evaluation findings regarding the strategies MAPs used to access 
priority groups, and the extent to which these strategies contributed to more equitable access and 
health outcomes. 
2.4.1. Access to health services and outcomes 
Accessing and meeting the needs of priority groups  
Enrolment 
Analysis of participant enrolment data found strong enrolment from priority groups. Participation 
by priority groups was higher than the ethnic distribution of the population amongst all people 
with OA in New Zealand.  
Nineteen percent of MAP participants (N = 907) were Māori, who comprise 11 percent of all 
people with OA in New Zealand. Nine percent of participants (N = 435) identified as Pasifika, who 
comprise 4 percent of the total New Zealand population with OA. Twenty-seven percent of 
participants (N = 1,228) were from the most deprived quintile of neighbourhoods, who comprise 
21 percent of all people with OA in New Zealand. There was wide variation in the participation by 
priority groups across programmes ( 
  
 
45 Ministry of Health (2017). Mobility Action Programme (MAP) Tranche 1 Providers: Assessment of equity for 
access to the MAP. Ministry of Health: Wellington. 
46 Ministry of Health (2017). Mobility Action Programme (MAP) Providers: Assessment of equity for access to 
the MAP (second report). Ministry of Health: Wellington. 
47 The first equity report pertains to data collected to 9 May 2017, and the second report pertains to data 
collected to 27 October 2017. 
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Table 9: Enrolment by provider and priority groups (counts and percentages) 
Programme Māori Pasifika Most deprived 
areas  
Programme 1 (N = 276) 25 (9%) 26 (9%) 43 (16%) 
Programme 2 (N = 459) 61 (13%) 143 (31%) 180 (39%) 
Programme 3 (N = 93) 44 (47%) 1 (1%) 58 (62%) 
Programme 4 (N = 160) 11 (7%) 0 (0%) 30 (19%) 
Programme 5 (N = 377) 61 (16%) 3 (1%) 65 (17%) 
Programme 6 (N = 161) 16 (10%) 1 (1%) 19 (12%) 
Programme 7 (N = 191) 30 (16%) 2 (1%) 37 (19%) 
Programme 8 (N = 296) 102 (34%) 5 (2%) 91 (31%) 
Programme 9 (N = 330) 274 (83%) 28 (8%) 192 (58%) 
Programme 10 (N = 237) 10 (4%) 140 (59%) 95 (40%) 
Programme 11 (N = 410) 137 (33%) 6 (1%) 165 (40%) 
Programme 12 (N = 486) 24 (5%) 9 (2%) 33 (7%) 
Programme 13 (N = 101) 1 (1%) 0 (0%) 5 (5%) 
Programme 14 (N = 245) 8 (3%) 6 (2%) 25 (10%) 
Programme 15 (N = 309) 26 (8%) 5 (2%) 43 (14%) 
Programme 16 (N = 364) 46 (13%) 21 (6%) 85 (23%) 
Programme 17 (N = 288) 31 (11%) 39 (14%) 62 (22%) 
Total = 4,783 907 (19%) 435 (9%) 1228 (26%) 
Most programmes had participation rates for priority groups similar to or greater than that 
group’s proportion of the total population with OA within their geographical region (Table 10).48 
In particular, Programme 3, Programme 7, Programme 9 and Programme 11 enrolled a high 
portion of Māori participants. Programme 2 and Programme 10 enrolled a high portion of Pasifika. 
  
 
48 These data were calculated by combining Statistics New Zealand 2018 Census data on the population 
sizes for each priority group with Ministry of Health NZ Health Survey on OA prevalence. 
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Table 10: Percentage of each priority population in the MAP participant cohort compared to the estimated 
proportion of the total population with OA within the geographic area 
Programme Māori Pasifika Most deprived areas 
Programme 1 9% of MAP cohort 
(7% of total popn 
with OA in this area) 
9% (8%) 17% (14%) 
Programme 2 13% (12%) 31% (17%) 44% (40%) 
Programme 3 47% (25%) 1% (2%) 65% (52%) 
Programme 4 7% (16%) 0% (1%) 19% (31%) 
Programme 5 16% (17%) 1% (1%) 19% (22%) 
Programme 6 10% (6%) 1% (1%) 12% (7%) 
Programme 7 16% (7%) 1% (4%) 20% (5%) 
Programme 8 34% (42%) 2% (2%) 31% (55%) 
Programme 9 83% (17%) 8% (2%) 60% (25%) 
Programme 10 4% (16%) 59% (2%) 44% (31%) 
Programme 11 33% (25%) 1% (2%) 43% (52%) 
Programme 12 5% (6%) 2% (1%) 7% (7%) 
Programme 13 1% (4%) 0% (0%) 6% (12%) 
Programme 14 3% (6%) 2% (1%) 11% (12%) 
Programme 15 8% (6%) 2% (1%) 15% (3%) 
Programme 16 13% (12%) 6% (3%) 24% (26%) 
Programme 17 11% (8%) 14% (6%) 22% (9%) 
Total 19% (11%) 9% (4%) 27% (21%) 
Overall, these findings suggest that the MAP has been successful in enrolling participants from 
priority groups. Because few programmes had specific enrolment targets based on priority 
groups, it is not meaningful to make comparisons between anticipated and achieved enrolment 
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Completion 
The evaluation also assessed the extent to which MAP participants remained with the programme 
until completion (Time 2). Findings suggest MAP was less successful in retaining participants from 
priority groups. 
Completion rates of 67 percent for Māori, 66 percent for Pasifika, and 69 percent for those in the 
most deprived neighbourhoods were significantly lower than the overall 78 percent completion 
rate for all participants.  
Programmes which achieved completion rates for Māori at or above the rate for all participants 
were Programme 7 (90% of Māori participants reached discharge), Programme 8 (82%), and 
Programme 12 (83%).  
For Pasifika, only Programme 10 achieved completion rates at or above the rate for all participants 
(82%).49 The number and percentages of the priority groups the remained with the MAP until 
completion for each programme are shown in Table 11. 
Table 11: Discharge volumes (and percentages of baseline enrolment) by provider and priority population 
Programme (Total completion volume; percentage) Māori Pasifika Most 
deprived 
areas 
Programme 1 (N = 179; 65) 15 (60%) 9 (35%) 21 (49%) 
Programme 2 (N = 301; 66) 30 (49%) 77 (54%) 94 (52%) 
Programme 3 (N = 64; 69) 26 (59%) 0 (0%) 38 (66%) 
Programme 4 (N = 96; 60) 8 (73%) ^ 18 (60%) 
Programme 5 (N = 306; 81) 43 (70%) 3 (100%) 52 (80%) 
Programme 6 (N = 133; 83) 9 (56%) 1 (100%) 13 (68%) 
Programme 7 (N = 170; 89) 27 (90%) 2 (100%) 34 (92%) 
Programme 8 (N = 257; 87) 84 (82%) 3 (60%) 71 (78%) 
Programme 9 (N = 228; 69) 189 (69%) 19 (68%) 135 (70%) 
Programme 10 (N = 201; 85) 8 (80%) 115 (82%) 78 (82%) 
Programme 11 (N = 266; 65) 70 (51%) 6 (100%) 102 (62%) 
Programme 12 (N = 423; 87) 20 (83%) 6 (67%) 23 (70%) 
Programme 13 (N = 98; 97) 1 (100%) ^ 5 (100%) 
Programme 14 (N = 202; 82) 8 (100%) 3 (50%) 19 (76%) 
Programme 15 (N = 246; 80) 20 (77%) 3 (60%) 35 (81%) 
 
49 Programmes that had fewer than eight participants in each population group have not been included, as 
the small sample size may distort the finding  
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Programme (Total completion volume; percentage) Māori Pasifika Most 
deprived 
areas 
Programme 16 (N = 316; 87) 32 (70%) 14 (67%) 75 (88%) 
Programme 17 (N = 229; 80) 21 (68%) 24 (62%) 38 (61%) 
Total (N = 3715; 78) 611 (67%) 285 (66%) 851 (69%) 
Note: cell counts report: count (% age of baseline enrolment); ^ indicates no baseline enrolment 
Provider strategies to engage MAP’s priority groups 
Providers implemented a range of strategies to help attract priority groups (i.e., Māori, Pasifika, 
and people living in high deprivation areas) and keep them engaged in the MAP. These strategies 
varied across providers and programme types (e.g., provider type, delivery method, programme 
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Table 12: Provider strategies to retain MAP priority groups 
Provider type Delivery method Programme duration Referral source 
Private Non-profit DHB Individual Group Less 10 weeks Over 10 weeks GP Self-referral Other 
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Barriers for engaging priority groups were also noted. One provider commented,  
“we have a good Māori health organisation in the region [but it is] not an organisation that we 
had done a lot of work with before prior to the launch of the MAP… we underestimated the time 
it takes to build those relationships and the trust and mutual respect which is so important in this 
space.” 
Other factors preventing better engagement with MAP’s priority groups included: 
• a lack of ethnic diversity and (in some instances) a lack of cultural awareness amongst 
healthcare workers and providers; and 
• societal norms and self-beliefs of how people understand MSK conditions and 
improvement (e.g., surgery as the only way forward; MSK conditions are just going to get 
worse; it’s just ‘old age’). 
Providers who offered individual sessions sometimes encountered challenges delivering lessons 
to women (e.g., having only male trainers available to train women when this might not be 
acceptable for religious or cultural reasons). These providers considered that having a more 
diverse workforce would have helped mitigate such, highlighting a wider systemic issue of the 
need for greater diversity in the allied health workforce. 
Priority groups and equity of outcomes 
Overall, findings indicate health outcomes were the same or better for priority groups compared 
to other participants. However, Pasifika participants had worse outcomes on some measures, 
especially mental health and general health-related quality of life (at Time 4 only). These findings 
are described in further detail below. 
Numerical Pain Rating Scale (NPRS) 
The figure below illustrates the degree of change between NPRS scores at Time 1 and Times 2 
through 4. All groups showed statistically significant reductions at all time points. Māori at Time 
4 and Pasifika at Time 3 had larger improvements in pain than non-Māori/non-Pasifika. 
Figure 16: Change in NPRS scores between Time 1 and Times 2 through 4, priority groups 
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Stanford Self-Efficacy Scale (SSES) 
All priority groups except for Pasifika (at Time 4 only) had statistically significant improvements 
in SSES scores. None of the differences between groups were statistically significant. 
Figure 17: Change in SSES scores between Time 1 and Times 2 through 4, priority groups 
 
Note. Higher values signify higher self-efficacy; error bars show 95% confidence intervals. 
Timed Up and Go (TU&G) 
All priority groups had statistically significant improvements in TU&G times at Time 2. There were 
no statistically significant differences between groups. 
Note. Shorter times signify better mobility; error bars show 95% confidence intervals. 
The Oxford Hip Score (OHS) 
All priority groups had improvements in OHS scores at all time points. There were no statistically 
significant differences between groups.  
Note: higher values signify better health outcomes; error bars show 95% confidence intervals; and * indicates 
a statistically significant change. 
  
Figure 18: Change in TU&G scores between Time 1 and Times 2 through 4, priority groups 
 




The Oxford Knee Score (OKS) 
All priority groups had improvements in OKS scores at all time points. Pasifika had significantly 
smaller improvements than other participants at Time 2 and Time 4. Participants from the most 
deprived neighbourhoods had significantly smaller improvements than other participants at Time 
3 only. 
Figure 20: Change in OKS scores between Time 1 and Times 2 through 4, priority groups 
 
Note: higher values signify better health outcomes; error bars show 95% confidence intervals; and * indicates 
a statistically significant change. 
The Roland-Morris Low Back Pain and Disability Questionnaire (RMDQ) 
All priority groups had statistically significant improvements in RMDQ scores at all time points. 
There were no statistically significant differences between groups. 
Note: lower values signify less disability; error bars show 95% confidence intervals; and * indicates a 
statistically significant change. 
The Lower Extremity Function Scale (LEFS) 
All priority groups had improvements in LEFS scores at all time points. Māori participants had 
significantly greater improvements at Time 4 and Pasifika participants at Time 3. 
Note: higher values signify better function; error bars show 95% confidence intervals; and * indicates 
statistically significant change. 
  
Figure 21: Change in RMDQ scores between Time 1 and Times 2 through 4, priority groups 
Figure 22: Change in LEFS scores between Time 1 and Times 2 through 4, priority groups 
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General health-related quality of life (SF-12) 
All priority groups had improvements in SF-12 PCS scores at both Time 3 and Time 4.  
Note: higher values signify better general physical health; error bars show 95% confidence intervals; and * 
indicates statistically significant change. 
All priority groups had improvements in SF-12 MCS scores at Time 3. Pasifika participants had 
significantly worse scores at Time 4 than Time 1. 
Note: higher values signify better general mental health; error bars show 95% confidence intervals; and * 
indicates statistically significant change. 
Two programmes (Programme 2 and Programme 10) performed better than other programmes 
on Pasifika general health and mental health indicators (data not presented). These programmes 
both had a large Pasifika population, and tried to tailor the programme to suit the cultural needs 
of Pasifika groups (for example, by starting sessions with prayer and having staff who spoke 
Pacific languages).  
All priority groups had improvements in SF-6D values at Time 3. All priority groups other than 
Pasifika had significant improvements in SF-6D values at Time 4. Pasifika participants had a non-
significant worsening in SF-6D values and significantly worse outcomes than non-Pasifika 
participants at Time 4. 
Note: higher values signify better general health-related quality of life; error bars show 95% confidence 
intervals; and * indicates statistically significant change. 
2.4.2. Reduction in disparities summary  
Evaluation findings regarding reducing disparities through the MAP show: 
• the MAP successfully enrolled Māori, Pasifika and participants living in deprived 
neighbourhoods when compared to wider population proportions with OA; 
• priority groups were less likely to remain with the MAP until completion; 
Figure 23: Change in SF-12 PCS scores between Time 1 and Times 2 through 4, priority groups 
Figure 24: Change in SF-12 MCS scores between Time 1 and Times 2 through 4, priority groups 
Figure 25: Change in SF-6D values between Time 1 and Times 2 through 4, priority groups 
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• participation rates for priority groups were generally similar to or greater than the 
estimated share of those populations among people with OA within their geographical 
region; and 
• there were few significant differences in health outcomes between priority group 
participants and other participants. However, Pasifika participants had worse outcomes 
on some measures, particularly mental health and general health-related quality of life (at 
Time 4).  
• MAPs that had a high portion of Pasifika participants and tailored the programme to 
Pasifika cultural needs performed better on these outcomes.  
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2.5. Economic impact 
2.5.1. Economic impact of the MAP 
The following section presents the economic impact of the MAP, including value for money 
considerations; potential health system savings; and wider economic impacts the MAP on 
employment/return to the workforce and work productivity.  
E1. Value for money  
Within the context of the MAP, ‘value for money’ for participants included: 
• improved quality of life, both with and without workforce participation; 
• decreased need for surgical intervention and reduced need for pain relief; and 
• increased community involvement. 
Providers and Ministry stakeholders considered that value for money was achieved by: 
• offering the MAP within a setting accustomed to providing interdisciplinary care to 
provide consistent communication, management and assessment processes; 
• offering group sessions (so long as the participant count is high enough) to enhance 
socialisation, a sense of belonging and enhanced awareness of one’s condition through 
comparison with others; 
• embedding the principles of self-management, self-care and education into the core of the 
programme; 
• providing the MAP in a setting with enough internal capacity to ensure succession 
planning and project continuity; and 
• creating resources and raising awareness of what people can access to help self-manage 
their condition. 
Providers and Ministry stakeholders considered that better value for money could have been 
achieved if: 
• participants were offered more efficient triaging services to determine primary OA 
concerns (versus other comorbidities) to ensure referrals were appropriate and to 
effectively triage to different service pathways; 
• participants were provided longer-term opportunities to embed new learnings on how to 
manage their condition and become involved in longer-term settings (e.g., an ongoing 
class or support group); 
• Telehealth was better utilised for ‘booster’ sessions; 
• PHOs were more closely engaged to help implement education sessions; and 
• MAP health outcome measures were streamlined. 
E2. Financial costs and savings for the health system and people with MSK conditions  
MAP participant data analysis used the following indicators of the MAP’s potential financial costs 
and savings to the health system: number of GP visits; specialist referrals; specialist visits; other 
visits; emergency department (ED) visits; admissions; and medical tests. 
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As proxy measures, it was assumed that reductions in these events over time would signify 
savings. As described in Section 2.2.1 (H6), there were small but statistically significant reductions 
in specialist referrals, specialist visits, and emergency department visits at Times 2 through 4 
compared to Time 1. 
Analysis of participant data also found significant reductions in the number of GP visits and 
diagnostic tests. Participants reported an average of 0.51 fewer GP visits (95 percent CI: 0.46 to 
0.56) in the three months to Time 2 compared to the same period to Time 1; 0.70 fewer (95 
percent CI: 0.65 to 0.75) at Time 3, and 0.72 fewer (95 percent CI: 0.66 to 0.77) at Time 4. They 
also reported 0.23 fewer diagnostic tests (95 percent CI: 0.20 to 0.26) at Time 2, 0.30 fewer (95 
percent CI: 0.32 to 0.27) at Time 3, and 0.29 fewer (95 percent CI: 0.26 to 0.32) at Time 4. 
Conversely, there was an increase in reported ‘other visits’ to healthcare services at Time 2 
compared to Time 1 (1.08 more; 95 percent CI: 0.95 to 1.21): this may reflect some participants 
recording MAP visits. Otherwise, there was a significant reduction in other visits reported at Time 
3 (0.37 fewer; 95 percent CI: 0.23 to 0.50) and Time 4 (0.49 fewer; 95 percent CI: 0.34 to 0.63) 
compared to Time 1. 
Table 13: Change in mean number of medical events reported between Time 1 and Times 2 through 4 (mean 
and 95% CI) 
Status Time 2 Time 3 Time 4 
GP Visits -0.51 (-0.56 to -0.46) -0.70 (-0.75 to -0.65) -0.72 (-0.77 to -0.66) 
Specialist Referrals -0.08 (-0.10 to -0.06) -0.12 (-0.14 to -0.10) -0.11 (-0.13 to -0.08) 
Specialist Visits -0.04 (-0.07 to -0.01) -0.09 (-0.12 to -0.05) -0.03 (-0.07 to 0.002) 
Other Visits 1.08 (0.95 to 1.21) -0.37 (-0.50 to -0.23) -0.49 (-0.63 to -0.34) 
ED Visits -0.01 (-0.03 to -0.002) -0.02 (-0.03 to -0.004) -0.03 (-0.04 to -0.01) 
Admissions 0.002 (-0.01 to 0.01) 0.01 (-0.002 to 0.02) 0.01 (0.0001 to 0.02) 
Tests -0.23 (-0.26 to -0.20) -0.30 (-0.32 to -0.27) -0.29 (-0.32 to -0.26) 
Cost-effectiveness 
Evidence of potential savings for the health system and MAP participants was also found through 
a cost-effectiveness analysis (see Appendix E) using the following outcome measures: the NPRS; 
TU&G; SF-12 PCS; SF-12 MCS; SF-6D; and number of GP visits. 
To estimate the treatment effect of the MAP, relative to expected outcomes without the 
programme, health outcomes of the MAP cohort were compared with those from another New 
Zealand-based OA intervention programme (the MOA trial).  
The MOA trial had a ‘usual care’ control group and an exercise therapy programme intervention. 
The exercise therapy intervention was similar to the exercise components of the MAP (and was 
explicitly used as the basis for several of these programmes). The MOA trial included a randomised 
control group and a longer follow-up period. Comparison of the MAP and MOA outcomes can be 
used to inform estimates of the expected longer-term outcomes of the MAP. The key assumption 
underlying these analyses is that the relationship between short-term and long-term outcomes 
observed in the MOA trial is similar to that yet to be observed in the MAP. 
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There were some important difference between the interventions. MOA trial participants were 
predominantly Pākehā/New Zealand European, and had slightly less severe pain and better TU&G 
test times than the MAP cohort at baseline (Table 15). MOA and MAP participants had similar 
health service use (GP visits) and SF-6D health utility (the primary health outcome used in the 
cost-effectiveness analysis).  
Table 14: Baseline characteristics of the MAP and MOA trial samples (score and S.E.) 
Outcome measure MAP MOA trial (usual care) MOA trial (exercise 
therapy) 
Numeric Pain Rating Scale 4.5 (2.0) 3.2 (2.0) 3.5 (2.0) 
Timed Up and Go test 11.0 (6.3) 7.8 (3.3) 7.5 (3.2) 
SF-12 Physical Component Summary 36.2 (9.0) 36.0 (10.4) 36.5 (10.7) 
SF-12 Mental Component Summary 48.2 (10.8) 51.6 (10.1) 53.4 (10.1) 
SF-6D health utility 0.65 (0.12) 0.68 (0.14) 0.70 (0.15) 
Number of GP visits 1.3 (1.5) 1.2 (0.9) 1.1 (0.8) 
To account for these differences, all comparisons of improvements in the MAP and MOA cohorts 
were adjusted for baseline health measures. These adjusted analyses showed that the overall 
effect size of the MAP on participants health-related quality of life was approximately 70 percent 
as large as observed in the MOA trial (see Appendix E). Based on these values, a validated 
computer simulation model of OA management was used to estimate the projected MAP cohort 
health improvements, healthcare costs, and cost-effectiveness at different time horizons to 15 
years.50 51 
Health gains were assessed using quality-adjusted life years (QALYs), a measure that combines 
both the magnitude of improvement in health-related quality of life (measured in this analysis by 
the SF-6D) and the length of time spent in the health state. (A gain of 1 QALY is equivalent to an 
additional year of life lived in perfect health.) As shown in  
Figure 26, total health gains over the short-term one-year horizon were estimated to be 155 QALYs 
in the MAP cohort (90 percent uncertainty interval [UI]: 104 to 204), or 0.03 QALYs per 
participant (90 percent UI: 0.022 to 0.043).  
 
50 MAP data could not be used to estimate longer-term healthcare costs (e.g., cost savings due to reductions 
in other health service use). An assumption was therefore made that costs would be proportional to savings 
observed in the long-term follow-up of MOA participants (i.e., 70 percent of cost savings observed in the 
MOA trial exercise therapy group aligned with 70 percent relative effectiveness in overall health-related 
quality of life outcomes). 
51 Cost savings were assumed to be realised from the second year and onwards (as only small reductions in 
health service use were observed in Time 4 data, which is consistent with MOA trial results). Further, direct 
programme costs were used for the first year of MAP only, and were based on budgeted per-participant 
costs using provider contracts. Results may therefore not reflect the actual costs of service delivery. As 
approximately 20 percent of providers’ budgets were allocated for data collection activities that would not 
be required in an operational model for the MAP, direct treatment costs were assumed to be 80 percent of 
budgeted per-participant costs. 
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Costs from budgeted per-participant costs (excluding the cost of data collection) were estimated 
at $3.6 million (90 percent UI: $3.2 to $3.9 million), or $743 per participant (90 percent UI: $668 
to $823). The resulting incremental net monetary benefit (INMB) was $5.4 million (90% UI: $2.3 
to $8.3 million),52 indicating the MAP was cost-effective over the short-term from the perspective 
of the healthcare system. 
Figure 26: Projected MAP cohort health gains; 1-, 3-, 5-, 10-, and 15-year time horizons 
 
There was more uncertainty in the projected longer-term outcomes, as these rely on the observed 
longer-term outcomes from the MOA trial with a much smaller sample size (50 participants in 
each of the usual care and exercise therapy groups) than the MAP. Over five years, the cumulative 
health gain in the MAP cohort was projected to be 549 QALYs (90 percent UI: 372 to 713), or 0.11 
per participant (90% UI: 0.08 to 0.15), with cost savings of $4.3 million (90 percent UI: $17.6 
million saving to $9.5 million increase), or $891 per participant (90% UI: $6,371 saving to $1,993 
increase).   
Findings on projected costs are very tentative due to the inherent variability in healthcare costs 
in small groups of individuals. However, the MAP was projected to be cost-effective over all time 
horizons with a high degree of confidence, as the large health gains outweigh the uncertainty in 
cost savings. As shown in Figure 27, the INMB over five years was $35.9 million (90 percent UI: 
$19.4 to $52.1 million). 
 
52 The INMB is a measure of the overall cost-effectiveness of an intervention from the perspective of the 
healthcare system, assuming a given level of willingness-to-pay (WTP) for healthcare to achieve a given 
health gain – in this analysis, WTP was assumed to be equivalent to Gross Domestic Product (GDP) per 
capita ($57,500 in 2017), as recommended by the WHO. 
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Figure 27: Projected MAP cohort incremental healthcare costs; 1-, 3-, 5-, 10-, and 15-year time horizons 
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Further, a sensitivity analysis (see Appendix E for details) using data from MAP participants with 
OA only gave almost identical results.53 
Figure 28: Projected MAP cohort incremental net monetary benefit; 1-, 3-, 5-, 10-, and 15-year time horizons 
 
 
MAP consumer survey results offered additional support of the aforementioned findings. Over 
half (54 percent) of respondents stated that attending the MAP reduced their medical costs. This 
effect was greater for those aged under 60, who were 1.4 time more likely to report paying less in 
medical costs as a result of attending the MAP than those aged 61 years or more (RR = 1.43, χ2 = 
5.52, p = .02). 
E3. Employment and productivity of MAP participants 
In addition to examining the potential cost-effectiveness of MAP, further assessment of MAP 
participant data suggested that the MAP helped increase participants’ productivity (Table 15). 
Specifically, MAP participants were less likely at Time 2, compared to Time 1, to report negative 
effects of their condition on the hours they were able to work (8 percent fewer participants; 95 
percent CI: 6 to 9 percent) or type of work they were able to do (9% fewer; 95% CI: 7% to 10%).  
MAP participants were also slightly less likely to report being unemployed for condition-related 
reasons at Time 2 (0.8 percent fewer participants; 95 percent CI: 0.1 to 1.5 percent).  
There were no significant changes between Time 2 compared to Time 1 in the proportion of 
participants in full-time or part-time work. 
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Similar improvements were also seen at later time points: 
• At Time 3, 8 percent fewer participants (95 percent CI: 6 to 10 percent) reported that their 
hours of work were affected by their condition, and 9 percent fewer (95 percent CI: 7 to 
11 percent) reported that their type of work was affected. 
• At Time 4, 10 percent fewer participants (95 percent CI: 8 to 11 percent) reported that 
their hours of work were affected by their condition, and 12 percent fewer (95 percent CI: 
10 to 14 percent) reported that their type of work was affected. 
• At Time 4, there were also reductions in the proportion of participants reporting being 
unemployed either for reasons related (0.8 percent; 95 percent CI: 0.1 to 1.6 percent) or 
unrelated (0.9 percent; 95 percent CI: 0.2 to 1.7 percent) to their condition. 
Conversely, analysis of MAP participant data also found a small reduction in the proportion of 
participants employed either full-time (1.4 percent fewer; 95 percent CI: 0.6 to 2.3 percent) or 
part-time (1.1 percent fewer; 95 percent CI: 0.1 to 2.0 percent) at Time 4; however, this decrease 
may reflect expected patterns of retirement in this age group rather than condition-related 
outcomes. 
Table 15: Change in MAP participants’ work status between Time 1 and Times 2 through 4 (percentages and 
95% CI) 
Status Time 1 Time 2 Time 3 Time 4 
Full-time 28.2 0.1 (-0.7 to 0.9) -0.5 (-1.3 to 0.3) -1.4 (-2.3 to -0.6) 
Part-time 14.0 -0.6 (-1.5 to 0.3) -0.8 (-1.7 to 0.2) -1.1 (-2.0 to -0.1) 
Retired 38.5 1.5 (0.7 to 2.4) 2.4 (1.5 to 3.3) 4.4 (3.4 to 5.3) 
Unemployed (related to 
condition) 
8.2 -0.8 (-1.5 to -0.1) -0.4 (-1.1 to 0.3) -0.8 (-1.6 to -0.1) 
Unemployed (unrelated to 
condition) 
5.7 -0.6 (-1.2 to 0.1) -0.7 (-1.4 to 0.05) -0.9 (-1.6 to -0.2) 
Duration of work affected (if in 
full- or part-time work) 
50.8 -8 (-9 to -6) -8 (-10 to -6) -10 (-12 to -8) 
Type of work affected (if in full- or 
part-time work) 
50.6 -9 (-10 to -7) -9 (-11 to -7) -12 (-14 to -10) 
Productivity results from the MAP participant data were generally supported by results from the 
MAP consumer survey. Slightly over half of survey respondents (59 percent) reported that the 
MAP had improved their ability to seek or return to work. Respondents identifying as Māori three 
times more likely than non-Māori to report an improvement in ability to seek or return to work 
(RR = .338, χ2 = 4.38, p = .04).  
Consumer survey results regarding MAP-related increases in the number of participants’ work 
and/or volunteer time were more ambiguous. Slightly less than half (41 percent) reported that 
the MAP increased their work and/or volunteer time, and non-Māori were 2.7 times more likely 
to report increased work and/or volunteer time than Māori (RR = 2.67, χ2 5.61, p = .018).  
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Those who attended grouped/mixed MAP sessions reported 2.5 times more likely to report 
increased work/volunteer time than those attending individual sessions (RR = 2.51, χ2 = 6.19, p = 
.01).  
2.5.2. Economic impact summary 
Evaluation findings about the economic impact of the MAP indicate that: 
• the programme’s value for money for participants was perceived to include improved 
quality of life, a decreased need for surgical intervention and reduced need for pain relief 
and increased community involvement; 
• the programme’s value for money for providers and the Ministry was best achieved 
through service environments with pre-existing processes and systems for 
interdisciplinary care, group (as opposed to individual) sessions, shorter-term (versus 
longer-term) programmes and settings with strong internal capacity and capability; and 
• value for money also involved embedding the principles of self-management, self-care 
and education into the core of the programme from the outset, including the provision 
of accessible resources participants could access to further help self-manage their 
condition.  
The cost-effectiveness of MAP was favourable regarding potential financial savings to the 
healthcare system through (as proxy indicators) small but statistically significant reductions in 
specialist referrals, specialist visits, and emergency department visits over time.  
Cost-effectiveness analyses suggested that: 
• total health gains were estimated to be 155 QALYs in the MAP cohort or 0.03 per 
participant; 
• costs from budgeted per-participant costs were estimated at $743 per participant ($3.6 
million total), resulting in INMB of $5.4 million. This indicates the MAP was cost-effective 
over the short-term from the perspective of the healthcare system; and 
• there was more uncertainty in the projected longer-term outcomes, but the cumulative 
health gain in the MAP cohort over five years was projected to be 549 QALYs (0.11 per 
participant) with cost savings of $891 per participant ($4.3 million total); and 
• the MAP was projected to be cost-effective over a five-year horizon and large health gains 
were seen to outweigh uncertainty in cost savings.  
Lastly, MAP consumer survey results and qualitative information offered additional support of the 
programme’s cost-effectiveness and contributions to enhanced productivity. In sum: 
• 54 percent of survey respondents stated that attending the MAP reduced their medical 
costs;  
• 59 percent of respondents reported improvements in their ability to either work or to seek 
work. Those identifying as Māori were three times more likely than non-Māori to report 
an improvement; and 
• MAP participants were less likely to report negative effects of their condition of their 
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2.6. Consumer experience 
This section describes the experiences of MAP participants via the consumer survey.54 Survey 
findings should be interpreted with some caution due to response bias. Comparisons of responses 
across programmes cannot be made due to variations in provider delivery, client demographics 
and programme locations. 
C1. The consumer experience 
MAP wait times and perceived acceptability of wait times 
Of those responding to the consumer survey (Table 16), over a third (36 percent) waited less than 
a week to start their programme. Nearly three-quarters (73 percent) started within a month, and 
the majority (91 percent) started within two months. Of some concern were the 35 clients (3.6 
percent) for whom it took more than four months from being referred to starting the programme.   
Table 16: MAP wait times before starting the programme (counts and % responding) 
Wait times Count 
Less than two weeks 347 (36%) 
Less than one month 350 (36%) 
Less than two months 173 (18%) 
Less than four months 57 (5.9%) 
More than four months 35 (3.6%) 
 
As shown in Figure 29 most providers started their clients in the programme within one month 
of referral,55 with only three programmes dropping below this (Programme 5 started 58 percent 
of respondents within a month; Programme 6 started 46 percent within a month; and Programme 
13 started 21 percent of respondents within a month). Virtually all providers had started 
respondents within four months, although seven respondents from Programme 13 reported that 
it had taken more than four months to start the programme. 
  
 
54 Appendix E providers further information about the survey’s development and distribution, as well as 
demographic details of the final survey sample. 
55 These exclude practices with less than ten consumer survey respondents: Programme 9 (N = 7) and 




Most respondents felt that the wait time was totally acceptable (67 percent) or acceptable (30 
percent), with women 1.5 times more likely to report totally acceptable wait times (RR = .68, χ2 = 
6.41, p = .01).  
Those attending MAPs via non-private rehabilitation providers (e.g., DHBs and NGOs) or MAPs 
run via a mix of providers were 1.7 times more likely to report acceptable wait times than those 
in MAPs run by private rehabilitation providers (RR = 1.71, χ2 = 7.2, p =.01). Last, those who were 
referred by their GP were 1.7 times more likely to report acceptable waiting times than those not 
referred by their GP such as self-referrals (RR = .59, χ2 = 7.52, p = .006). 
Participants’ understanding of MAP pre-enrolment  
Three-quarters of respondents (76 percent) said they understood what the MAP was about. 
However: 
• 24 respondents wanted a fuller description of the programme pre-enrolment; 
• 15 respondents would have liked to know more about programme availability; and 
• 4 respondents would have preferred receiving an outline of programme courses/sessions 
pre-enrolment.   
Accessibility and attendance 
The majority of survey respondents perceived the MAP’s accessibility as very favourable. A very 
high proportion reported the MAP was: 
• held at a place that was easy for them to get to (93 percent); 
• suited for people with their health conditions (98 percent); and 
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• offered on days of the week that suited them (94 percent) and times that suited them (93 
percent). 
Eight respondents that said their MAP’s times did not suit and wanted them held outside of work 
hours.  
Respondents also report very high programme attendance. Three-quarters attended all the MAP 
exercise sessions (73 percent) and education sessions (74 percent). Reasons for non-attendance 
in all sessions included: 
• work commitments (24 percent); 
• health problems (22 percent); and 
• personal issues (17 percent). 
Care decisions and overall consumer experience of MAP 
Respondents were generally satisfied with the care decisions made with and for them in the MAP. 
Most (84 percent) felt that they were involved in decisions about their care, in contrast to 4.5 
percent who said they were not included and would have liked to have been. A small proportion 
(8 percent) preferred decisions to be made by others. Further, nearly all respondents were 
comfortable with how staff talked to them during MAP classes and at appointments (98 percent) 
and with how MAP was explained to them (99 percent).   
 
Overall, the majority (86 percent) of respondents were happy with their experience of the MAP 
(Figure 30). There were no significant differences by age, gender, ethnicity, or provider type. 
  
Figure 30: Happiness with MAP experience 
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2.6.1. Consumer experience summary 
Respondents from the consumer survey overwhelmingly reported multiple health benefits from 
participation in the MAP (reported in Section Error! Reference source not found.0). In terms of s
urvey respondents’ perceptions of MAP reported in the above section: 
• wait times for starting the MAP were generally between one to two months and most 
respondents perceived this to be acceptable; 
• a small number of respondents (N = 35) reported waiting more than four months to begin 
the programme; 
• 76 percent of respondents understood the MAP’s purpose before starting the programme, 
though some would have liked additional information about the programme, specific 
courses and its availability;  
• accessibility of the MAP was viewed very positively, with the majority of respondents 
reporting that locations and days/times of sessions suited them and their conditions; 
• respondents reported high attendance to MAP exercise and education sessions, with some 
unable to attend all sessions due to work commitments, health or personal issues; 
• most respondents felt they helped make decisions about their care and nearly all were 
comfortable with how staff talked to them during MAP classes, appointments, and how the 
MAP was explained to them; and 
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2.7. What works best 
As mentioned in Section 1.3, Cycle 2 of the evaluation emphasised the evaluation criterion “What 
works best”, particularly through consideration of the following four programme characteristics 
(see also Appendix D):  
• provider type; 
• delivery method; 
• programme duration; and 
• main referral source. 
With this in mind, the following section outlines the conditions in which the MAP was found to 
work best with specific consideration of the: 
• structures, approaches and programme components that provide the most benefits; 
• other factors that contributed to the success of the MAP, and that should be retained if the 
programme is rolled out to areas beyond the initial MAP locations. 
2.7.1. Structures, approaches and programme components providing greatest benefits 
Provider type 
The evaluation found that MAPs delivered by private providers were more likely to achieve 
statistically significant improvements in health outcomes than those delivered by a mix of 
provider types (e.g., DHBs and non-profits).  
Private providers were also found to offer the best accessibility and flexibility for MAP 
participants. Private rehabilitation agencies offered participants a wide range of MAP locations 
and several different session times and days. Private rehabilitation organisations also offered the 
greatest flexibility: they could change how they delivered their MAPs to suit participants and could 
more easily hire additional resources when required (e.g., pharmacists, additional trainers).  
MAPs delivered by a mix of provider types (e.g., DHBs and non-profits) performed better in 
achieving their anticipated enrolment volumes. These programmes were seen to offer the benefit 
of drawing on existing networks of primary health care practitioners and other referrers. There 
is also some evidence that mixed providers, including NGOs, are more effective in enrolling and 
retaining Māori and Pasifika participants.  
Delivery method 
The evidence shows that group sessions are the most effective delivery mechanism for achieving 
health outcomes, and that programmes offering group sessions performed best in retaining 
participants until completion. 
Group sessions enhanced participants’ sense of belonging and offered opportunities for 
socialising and making connections with people with similar conditions. Group sessions also 
enabled participants to establish support networks to help keep them involved in exercises and 
other self-management routines post-discharge.  
On the other hand, individual-based programmes offered the benefit for tailoring advice and 
addressing individual participant needs, which was particularly critical at the beginning stage of 
the programme. This ability to better tailor personal programmes helped bolster participants’ 
sense of ease, independence and confidence to self-manage their conditions, to better implement 
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their care plans and to offset challenges encountered when participants had more complex needs. 
Individual sessions also offered participants more privacy, and the ability to collaborate and 
engage with physios and other trainers one-on-one.  
Programme duration 
The evaluation findings show that longer-duration programmes (10 weeks and more) had 
consistently larger improvements in all health outcomes and offered (compared to shorter-term 
programmes) better healthcare gains, savings and cost-effectiveness.  
Longer-term programmes were less intensive for participants (e.g., fewer programme-related 
meetings or commitments per week) and offered them and providers more of an opportunity to 
address longer-term lifestyle changes, or more complex or severe health issues. Longer-term 
programmes also created more windows of opportunity to build rapport and relationships with 
community-based groups.  
Qualitative data from participants and MAP providers suggested that shorter-term programmes 
enabled people to commit more easily and helped sustain their motivation to complete the 
programme. However, this is not evidenced in the quantitative data which shows no clear trend 
in enrolment or completion rates by programme duration. 
Referral source 
There was no observable difference in performance on health outcomes, programme reach, or 
cost effectiveness of programmes with GP referrals compared to those with other referral sources. 
Qualitative data suggests that using a mix of referral sources offered the greatest benefits for both 
participants and providers. A broad referral network ensured information about and awareness 
of the MAP was distributed in a timely and less time-consuming way. A mix of referral sources 
also enhanced the accessibility of the programme. 
MAP providers perceived that GP referrals were successful at recruiting participants into MAP if 
GPs: 1) knew about the MAP; 2) bought into the programme’s philosophy; 3) had existing 
relationships with the MAP provider; 4) understood and applied the programme’s enrolment 
criteria; and 5) were willing to spend the additional time with clients to discuss the MAP and make 
the programme referral.  
2.7.2. Models or components that should be sustained, scaled up and adapted 
The following summary outlines components of the MAP that should be sustained, scaled up or 
adapted based on both quantitative and qualitative evaluation analyses. 
Selection of MAP service providers 
As well as evidence supporting the effectiveness of MAPs delivered by private providers, the 
evaluation found that it is important to select providers accustomed to interdisciplinary care. It is 
also important that providers have capability and experience in working with the priority 




 Mobility Action Programme (MAP) Evaluation Cycle 2 Final Report 55 
Awareness raising  
Achieving strong enrolment rates relies on good referrer and consumer awareness of the 
programme. It is important to allow time to build relationships between providers, referrers and 
the target population groups before the programme begins. Relationship building and referrals 
can be expedited by using existing links with primary care providers, other (ideally community-
based) healthcare providers and the local community. 
Eligibility criteria and triage processes  
Effective triaging services at the point of referral are an enabler for participants to get the most 
out of the MAP. Triaging should determine primary MSK condition (versus other comorbidities) 
to effectively triage to different service pathways. Equally important is to ensure referred 
participants meet the eligibility criteria for the programme; those with more severe MSK 
conditions were less likely to experience benefits from the MAP and emphasis should be placed 
on those with early-stage conditions. 
Equity focus 
MAPs that were most successful in enrolling and retaining priority groups were those that 
incorporated an equity focus from the beginning, using specific strategies to target these groups. 
Feedback from Māori and Pasifika participants also indicates that a MAP workforce with ethnic 
diversity and/or cultural competence increased their likelihood of remaining in the programme. 
Offering support to get financial assistance (e.g., via Work and Income) for participants in areas of 
high deprivation to purchase resources such as appropriate clothing was an enabler to 
participation for some groups. 
Programme accessibility 
The most effective MAPs made efforts to enhance programme availability and accessibility, by 
holding sessions in central community locations, delivering sessions in evenings or weekends, 
providing transport, and supporting participants with childcare options. Charging a fee to 
participate was a barrier to programme access. 
Programme delivery 
Successful programme delivery features included meeting with participants individually at the 
beginning of the programme to build buy-in and understanding, and to collaboratively design an 
individual care plan. 
During programme delivery, providers who emphasised self-management principles were more 
successful than those who implemented a ‘hands on’ approach that decreases participants’ locus 
of control. In terms of the programme delivery model, tiered treatment pathways were 
underutilised and overly complex with single pathways likely to be a better approach. 
Completion rates  
Completion rates were strongest for programmes that held individual meetings at the outset to 
build rapport with participants, enhance buy-in into the programme, and set expectations around 







3. EVALUATION CONCLUSIONS 
Overall conclusion 
The evaluation provides strong evidence that the MAP is an effective early intervention 
programme for people with MSK conditions. The MAP has resulted in health outcome gains for 
its participants, with the priority population groups achieving similar or better improvements 
in health status.  
The evaluation has also demonstrated that the MAP is a prudent investment, with evidence 
showing it was cost-effective over the short-term, achieving estimated health gains of 155 
quality-adjusted life years (QALYs) in the MAP cohort and incremental net monetary benefit 
(INMB) of $5.4 million. The MAP is projected to be highly cost-effective over a five-year horizon.  
The evaluation concludes that investment in early intervention programmes for MSK 
conditions represents good value for money. The specific focus of the MAP on priority groups 
contributes to health equity for Māori, Pasifika and those living in areas of higher derivation. 
KEQ1: What impact has the MAP had on general health status, pain, functional status, self-
confidence and ability of participants to self-manage their condition? 
 
 
Quantitative evidence from the evaluation shows that there was a reduction in the MAP cohort 
BMI from the beginning of the programme to completion, and that this was maintained or 
improved at subsequent measurement points. The analysis also found statistically significant 
improvements for pain, mobility and functionality as well as significant improvements in general 
health and wellbeing between the time of  entry into their MAP (baseline) and all other timepoints.  
Importantly, the MAP was also shown to be effective in its objectives of reducing demand on 
secondary healthcare services. MAP participant data analyses found statistically significant 
reductions in specialist referrals, specialist visits and emergency department visits. These health 
outcome findings were observed across most of the MAP pilot sites, indicating that the programme 





Below expectations (with some 
positive achievements) 
No change or detrimental 
There is strong evidence that participation in 
the MAP results in an increase in health-
enhancing behaviours, reduced pain, enhanced 
mobility and functionality, enhanced wellbeing 
and reduced need for secondary healthcare 
services. Based on these evaluative criteria, 
the programme’s effectiveness in improving 
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KEQ2: To what extent has the MAP reached its anticipated enrolment and completion rates? 
On average, the MAP is performing well at enabling access to the programme. The majority of 
MAPs (11 out of 17 programmes) reached least 80 percent of their target enrolment numbers. 
Completion rates were slightly lower, with nine of the MAPs achieving completion rates of at least 
80 percent. Across all programmes, 78% of participants completed their programme to the point 
of discharge (Time 2). 
Effective practices that increased enrolment and completion rates included a triaging system to 
ensure those referred to the programme are eligible (i.e., early stage MSK conditions), meeting 
individually with participants are the beginning to ensure buy in and set expectations, and offering 
practical assistance such as transport or childcare. 
KEQ3: To what extent is the MAP reducing known disparities in access to health services and 
outcomes? 
 
The evaluation found the MAP has been successful in enrolling participants from priority groups. 
Māori, Pasifika and people living in areas of higher deprivation were enrolled in the MAP at a 
higher rate than these groups’ proportion of the total population with arthritis in New Zealand.  
However, the MAP was less successful in retaining priority groups in the programme. The 
percentage of Māori, Pasifika and those in the most deprived neighbourhoods that remained with 
the programme until completion were lower than the overall completion rate for all participants. 
Health outcomes were similar for participants from priority groups compared to other 




Below expectations (with some 
positive achievements) 
No change or detrimental 
REDUCTION IN DISPARITIES 
Exceeded expectations 
Met expectations 
Below expectations (with some 
positive achievements) 
No change or detrimental 
The MAP effectively enrolled Māori, Pasifika 
and those living in high deprivation. It did not 
effectively retain these priority groups to 
completion. Health outcomes for these groups 
were relatively similar to the general MAP 
cohort. Based on these evaluative criteria, 
reduction in disparities met expectations. 
Most MAPs met anticipated enrolment rates 
and over half of the MAPs achieved acceptable 
completion rates. Based on these evaluative 
criteria, programme reach met expectations. 
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average; for example, Māori and Pasifika participants had larger reductions in pain than non-
Māori/non-Pasifika. 
However, Pasifika participants had worse outcomes on some measures, especially mental health 
and general health-related quality of life. Programmes with a high Pasifika enrolment numbers 
that were tailored to suit the cultural needs of Pacific peoples performed better on these 
outcomes.  
Participant survey data also shows positive outcomes for priority groups, particularly Māori. 
Respondents identifying as Māori were 3.6 times more likely to report health improvements than 
non-Māori. Māori were also more likely to report they learned how to manage their weight and 
were more likely to report an improved ability to seek or return to working following MAP.  
KEQ4: What was the economic impact of the MAP? 
The evaluation findings were favourable regarding the MAP’s potential financial savings to the 
healthcare system through (as proxy indicators) small but statistically significant reductions in 
specialist referrals, specialist visits, and emergency department visits over time.  
Total health gains were estimated to be 155 quality-adjusted life years (QALYs) in the MAP cohort 
or 0.03 per participant. 
Costs from budgeted per-participant costs were estimated at $743 per participant ($3.6 million 
total), resulting in incremental net monetary benefit (INMB) of $5.4 million. This indicates the 
MAP was cost-effective over the short-term from the perspective of the healthcare system.  
While there is more uncertainty in the projected longer-term outcomes, the MAP is projected to 
be highly cost-effective over a five-year horizon. The cumulative health gain over five years was 





Below expectations (with some 
positive achievements) 
No change or detrimental 
The MAP achieved an estimated health gain of 
155 QALYs in the MAP cohort and an INMB of 
$5.4M. It is projected to be cost-effective over 
a five-year horizon. Based on these evaluative 
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KEQ5: How well has the programme managed patient care? 
 
The evaluation found that most MAP participants were happy with their experience. They 
experienced acceptable wait times to start the MAP, were well informed about the programme’s 
purpose, and reported that locations and days/times of sessions suited them and their conditions. 
Participants considered that they MAP had helped then to better manage their MSK conditions. 
KEQ6: Under what conditions does the programme work best? 
The evaluation found that MAPs delivered by private providers performed best in achieving 
statistically significant improvements in participant health and offered better accessibility and 
flexibility for participants.  
MAPs delivered by a mix of provider types (e.g. DHBs and NGOs) performed better in achieving 
their anticipated enrolment volumes. 
Group sessions were the most effective delivery mechanism for achieving health outcomes and 
performed best in retaining participants until discharge. 
Longer-duration programmes (10 weeks and more) had consistently larger improvements in 
all health outcomes and offered (compared to shorter-term programmes) better healthcare gains, 
savings and cost-effectiveness.  
There was no observable difference in performance on health outcomes, programme reach, or 
cost effectiveness of that only accepted GP referrals compared to those with that accepted 
referrals from other sources. 
Other features associated with MAP effectiveness include: 
• programmes delivered by providers accustomed to interdisciplinary care models;  
• provider experience in working with the priority population groups; 
• building in time at the beginning of the programme to build relationships between 
providers, referrers and community groups; 
• ensuring effective triaging services at the point of programme referral; 





Below expectations (with some 
positive achievements) 
No change or detrimental 
The MAP mostly meets consumer needs and 
expectations and helped them self-manage 
their conditions. Based on these evaluative 
criteria, the programme’s consumer 
experience met expectations. 
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• ensuring MAPs were delivered in convenient locations, close to transport and with a range 
of session times including evenings or weekends; 
• meeting with participants individually at the beginning of the programme to build buy-in 
and understanding and to collaboratively design an individual care plan; 
• emphasising participant self-management of their conditions; and 
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4. RECOMMENDATIONS 
Based on the findings and conclusions described in this report, the evaluation makes the following 
recommendations 
1. The evaluation recommends an expanded roll out of the MAP or similar programmes. 
The pilot phase of the MAP has demonstrated that the programme offers health improvements to 
people with early stage MSK conditions, is effective at reaching its targeted population groups, is 
cost-effective and is well regarded by its participants. This provides a strong rationale for a wider 
roll out of the programme. 
2. Models should incorporate the features that have been shown to be effective. 
While there remains a need to target the design of individual MAPs to the context in which they 
are being delivered, programme design should be mindful of the evidence identified through this 
evaluation. This suggests that programmes should prioritise holding group sessions (with an 
initial individual meeting to gain buy in and design a care plan) and should generally be of longer 
duration. Private providers and mixed provider programmes both offered advantages and should 
continue to be supported.  
In addition, programme design needs to incorporate enablers of success that include a triaging 
system for referrals, implementation of evidence informed strategies to target priority groups, 
holding sessions at convenient locations and times, flexibility around times, emphasising self-
management of conditions. 
3. Focus on improving programme completion rates for priority groups. 
Completion rates were lower than anticipated for priority groups. The evaluative evidence shows 
MAPs that embedded an equity focus and developed strategies to recruit and retain priority 
groups from the start were most successful in retaining these groups. Success factors for retaining 
priority groups included having previous experience in working with the priority population, 
culturally diverse and culturally competent staff, and ensuring accessibility of the programme by 
holding the sessions at convenient locations and times. 
4. Strategies that ensure equity of outcomes for Pasifika should be a core component of 
the programme. 
Pasifika participants had worse outcomes on some measures, especially mental health and 
general health-related quality of life. MAPs in areas with high Pasifika populations should tailor 
the programme to ensure it meets their needs. This might include contracting Pasifika providers 
to deliver the service, and working with Pasifika health advisors or community representatives to 
ensure the programme is delivered in a culturally appropriate manner (for example, by starting 
sessions with prayer). 
5. Consider adapting the programme for participants with comorbidities/complex needs. 
The evaluation found that the MAP in its current design works best for those in the early stages of 
osteoarthritis as their primary health concern. Those with comorbidities (such as diabetes or 
cardiovascular conditions) are also likely to benefit from the MAP but struggled to participate in 
some programme activities and were more likely to leave the programme before completion. The 
evaluation recommends investigating the feasibility of offering specific programmes or add-
on/booster sessions targeting participants with comorbidities or more complex health needs. 
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6. Offer opportunities for post-programme support to embed self-management 
behaviours. 
Engagement with MAP participant found that they valued the social aspect of MAP group sessions 
and were motivated by the ongoing contact and support from other participants and MAP staff. 
However, this typically ceased after the programme ended. The evaluation recommends 
investigating the development of post-MAP support networks or other longer-term opportunities 
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APPENDIX A: GLOSSARY 
Term Description 
MAP The Mobility Action Programme (the programme). The Mobility Action 
Programme is a pilot initiative established to improve treatment for people who 
are prone to or live with orthopaedic and MSK conditions. MAP contract holders 
each deliver tailored, individualised MAPs (see below) under the wider 
programme. 
MAPs The pilot sites contracted by the Ministry of Health to deliver the MAP (N = 17 
total). The 17 MAP pilot programmes or MAPs vary in size, approach, duration, 
structure, price, populations targeted, conditions treated, localities, and type of 
services provided. 
Service providers The individuals and organisations who hold a contract with the Ministry of 
Health as one of the 17 MAPS to deliver the wider programme. 
MAP participants People with MSK health conditions who have participated in one of the 17 
MAPs. 
Key informants Individuals identified as having a key role in the design, development, 
implementation and outcomes of the MAP. This includes Ministry of Health 
staff, sector experts and representatives who belong to professional bodies and 
advocacy groups. 
Document review A review of MAP documents including programme design information, 
contracts and relevant research. The document review was initially undertaken 
during evaluation planning and design and is continually updated as additional 
information is received. 
Case study A data collection activity used in the first evaluation cycle that includes 
interviews, focus groups, focus group questionnaires and review of site-specific 
information. Five MAP site visits were conducted to document and examine 
their unique contexts, characteristics, and experiences with delivering the MAP. 
MAP participant focus 
group 
Part of the case study data collection method where a group of MAP 
participants were brought together to discuss their experience of the MAP 
Case study MAP 
participant focus group 
questionnaire 
A short questionnaire designed as part of the case studies for MAP focus group 
participants to complete during the focus group session. 
Virtual focus group with 
non-case study service 
providers 
An online focus group designed to collect information about the MAP from non-
case study service providers. 
MAP participant data All 17 MAPs were required to provide data to the Ministry of Health about MAP 
participants at four different time points (baseline or entry into the programme, 
discharge from the programme, three-months after discharge and 12-months 
after discharge). These data include clinical information (e.g., height, diagnosis, 
referral source, comorbid health conditions); health status (quality of life, 
condition-specific measures); and demographic information (e.g., age, ethnicity, 




MAP consumer survey A survey developed by Allen + Clarke in collaboration with the Ministry of Health 
to assess MAP participants’ perceptions and experience of the MAP. The survey 
includes the entire MAP cohort.  
IDI data The Integrated Data Infrastructure is a large research database containing 
microdata about people and households in New Zealand. The data are sourced 
from a range of government agencies, Statistics New Zealand surveys, and non-
government agencies. An application process was required for the MAP 
evaluation team to access and utilise IDI data. 
OA Osteoarthritis.  
OAHK Osteoarthritis of the Hip and Knee. 
LBP Lower Back Pain. 
The Green Prescription 
programme 
Written advice from a health professional for a patient to become more active 
and improve diet. Referrals for Green Prescription help support prevention and 
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APPENDIX B: ABOUT THE MOBILITY ACTION PROGRAMMES 
The table below was developed using information from the contracts between the Ministry and service providers with the exception of treatment 
target figures.56 







Programme 1 Four treatment pathways: 
• Advice and an exercise prescription, referral 
back to GP with recommendation for Green 
Prescription 
• Stage 1: Physio-led group programme 2.5hrs * 
six weeks, including exercise and education 
Stage 2: (as required) The Stanford Model of 
Self-Management of Chronic Pain Programme: 
2.5hrs * six weeks, to build confidence to self-
manage 
• Mild to moderate LBP: Pathway 2, plus up to 3 
interventions with MDT member(s) 
• More severe LBP: Pathway 2, plus advice and 
an exercise prescription with referral to GP 
recommending referral to secondary care). 
One-on-one; 
Group 
OAHK 360 Nil 
Programme 2 Four treatment pathways: 
• Assessment, advice, home exercise programme 
Group Osteoarthritis of the 
hip and knee (OAHK) 
550 Nil 
 
56 Treatment targets listed in the table were taken from those outlined in the contract between the Ministry and Allen + Clarke. 
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• Assessment, advice, group physio and 
education programme 
• Pathway 2 is preceded by brief individual 
psychological, medical, nutritional, and/or 
physical therapy 
• Not suited to MAP: referred back to referrer 
Programme 3 Four treatment pathways: 
• Advice and exercise prescription; referral back 
to GP for Green Prescription 
• Six-week exercise and education, using 
instructional videos 
• One-to-one intervention (as necessary), then to 
Pathway 2. 
• Advice and exercise prescription, 
recommendation to GP to refer to secondary 
care 
Group OAHK; low back pain 
(LBP) 
171 Nil 
Programme 4 Eight self-management modules and a personal 
health coach (accessed fortnightly), delivered over 
16 weeks. Coaching includes: 
Goal setting; understanding osteoarthritis; 
symptom/pain management; physical activity; 
health y eating; emotional wellness; sleep; 
communication for self-management 
Web-based OAHK 450 Not specified 
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• One-on-one 60-minute self-management 
session: condensed education, handouts 
supporting 12 weeks home-based exercise 
• Monthly 1.5 hr group session for three months, 
covering exercise and education; 
two one-hour exercise sessions per week for 
three months; up to two one-hour private 
physiotherapy sessions 
• 12-week programme: 
Exercise and education sessions, supplemented 
by 1 hour sessions with nutritionist and a one-
hour session with an occupational therapist; 
and up to six 30-minute appointment with a 
physiotherapist 
• Up to six surcharged physiotherapy sessions, 
and a discounted short-term gym or pool 
membership or assistance to attain a green 
prescription 
arthritis of the lower 
limbs and LBP 
Programme 6 Ten-week programme includes one hour of exercise 
and one hour of education 
Group Chronic and severe 
OAHK 
480 Nil 
Programme 7 Two treatment pathways: 
• Eight-week education and exercise programme, 
each session being for two hours, with follow-
up sessions at + one month and +two months; 
two 90-minute sessions with occupational 
therapists and physiotherapists are intended 
Group; one-
on-one 












for whānau/partners, and run concurrent with 
programme; 
• For people with more severe conditions, an 
assessment with MDT; personal goal setting; up 
to 10 sessions with allied health workers 
(aligned with personal needs). 
Programme 8 Six-week programme, one session of 90 minutes per 
week, including 15-minute presentations from allied 
health professionals; plus, a 30-minute cultural 
heritage walk for people referred through a kaupapa 
Māori provider; and a one-off follow-up 
consultation three months after completion. 
At the discretion of the physiotherapist, additional 




Mild to moderate 
OAHK 
288 Nil 
Programme 9 Physiotherapy component (three months); plus, a 
self-management course of six to eight weeks 
(which may run in parallel with the physiotherapy 




Mild to moderate 
MSK conditions 
400 Nil 
Programme 10 Four treatment pathways: 
• Four weeks with access as needed to 
physiotherapist review, weekly group exercise 
and nutrition sessions, monthly community 
education and exercise; reassessment by MDT 
for possible referral for specialist treatment 
One-on-one; 
Group 
OAHK; gout 350 Nil 
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• Eight week programme: as above, plus 
nutrition review, medication review, pain 
management plan 
• Twelve week programme: as above, plus 
individualised home-based exercise plan, 
weight-loss / nutrition plan 
• Not suited to MAP: referred back to GP with 
recommendation for specialist referral 
Programme 11 Three treatment pathways: 
• Individual strength and conditioning 
programme: five one-hour sessions over 8 – 10 
weeks; Green Prescription for swimming pool 
or gym; clinical pharmacist review; weight 
management; Brief Motivational Interviewing 
with physiotherapist at every session; referral 
to MDT as required 
• Physiotherapy-led small-group sessions (up to 
10 sessions over 3 months), weight 
management, clinical pharmacist review; Green 
Prescription; and where appropriate: intra-
articular or ultrasound-guided corticosteroids, 
mental health counselling if appropriate, 
walking assessment 
• Physiotherapy-led strength and condition 
programme – up to 20 sessions over 4 months; 
fortnightly weigh-in, medication and pain 
Individual; 
Group 
Mild to moderate 
MSK conditions, 
including OAHK, 
shoulder pain, LBP, 
and other MSK 















review, walking assessment, and where 
appropriate: intra-articular or ultrasound-
guided corticosteroids, mental health 
counselling if appropriate, balneotherapy, 
walking assessment 
Programme 12 Two treatment pathways: 
• Mild: Individually tailored home exercise 
programme with ongoing support over 12 
weeks; education via 
videos/podcasts/handouts/internet links, 
covering understand osteoarthritis, managing 
osteoarthritis, physical activity for 
osteoarthritis, diet and weight management, 
pain management, pacing load management 
and aids for managing your environment. 
• Moderate: Up to five hours one-on-one with 
physiotherapist, developing individually tailed 
rehab programme; progressing to group 
strength and conditioning sessions – small 
groups over six weeks, and including 15 mins 
education + 45 mins exercise; tailed home 
exercise programme; education and self-
management tools as for Pathway 1; pain 
management; referral to allied health services 
as appropriate; referral for Green Prescription 
etc 
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Programme 13 A 12-week, one-hour group exercise class, with 
individualised exercises according to need; an 
education session at week 6; four weeks home 
exercise supported by weekly phone calls by class 
physiotherapist; face-to-face review at 17 weeks; 
phone reviews at 3, 12, and 24 months; referral to 
MDT as required 






part payment of 
$150 
Programme 14 Core programme: education programme covering 
disease management; individualised exercise 
programme; pharmacological assessment; links to 
community groups 
Additional services (if indicted): manual therapy; 
home visit for functional assessment; psychological 
management, weight loss support 
One-on-one; 
Group 
OAHK 300 Nil 
Programme 16 Four treatment pathways, each varying by the 
number of sessions that follow an initial assessment 
• 3 – 8 sessions 
• 9 – 25 sessions 
• 13 – 30 sessions, and 
• 19 – 38 sessions 
Core components of the sessions include: 
physiotherapy assessment; education modules 
(individual and groups); supervised and grade 
exercise and functional reactivation; community-
based activity; individualised sessions as required 
with MDT members; referral to community support 
networks, follow session. 
One-on-one; 
Group 
Chronic OAHK; LBP; 
and 
Chronic OAHK 
375 50% to pay 25% 











Programme 15 Primary Care Training: 
Modules facilitated by an orthopaedic spine 
specialist, to improve GP understanding, assessment 
and non-pharmacological treatment of LBP at 
primary health care level. 
 
Community MSK Advice: Two Pathways: 
• Remote Care: Weekly telehealth support (up to 
one hour), for six weeks; access to on-line 
resources covering education, exercise-based 
applications and electronic exercise resources 
• Group Rehab: six-week exercise programme in 
a group of 6 – 12 people, covering 
strengthening, stretching and cardio fitness, 
informal education, access to in-line resources 
Remote Care and Group Rehab pathways both 
include group education evenings held quarterly, 
each comprising four 20-minute presentations from 
allied health professionals (spine specialist, 
physiotherapist, psychologist, and dietician); 




LBP 306 Non-community 
service card 
holder charged a 
maximum of $15 
per session of 
individualised 
rehab, and $5 per 
session for group 
exercise 
programme 
Programme 17 Two treatment pathways: 
• Simple: up to five sessions with physiotherapist 
focusing on strength and conditioning training 
and wellness education 
One-on-one Mild to moderate 
OAHK 
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• Complex: up to eight sessions with MDT 
members for additional assessment, treatment, 
rehabilitation, wellness 
referrals from 
other sources to 




specified); and of 
these, those with 
a community 
services card to 





APPENDIX C: DESIRED ACHIEVEMENTS AND EVALUATIVE ASSESSMENTS 
Criteria Desired achievements Performance indicators Sources of information 




(H1) MAP participants modify 
behaviours in order to improve 
health outcomes 
• MAP participants report increased physical activity, 
which they attribute to the MAP  
• Analysis of MAP participant data shows a reduction in 
cohort BMI from entry to completion of the MAP 
• MAP participants report increased knowledge of health 
behaviours (e.g., reduced tobacco use, better diet and 
weight management) gained through the MAP 
• Interviews 
• MAP participant data  
• Consumer survey 
• Consumer focus groups 
• Virtual provider focus 
groups 
(H2) Participation in the MAP results 
in reduced reported pain for 
people with MSK health 
conditions 
• Analysis of MAP participant data shows improvement in 
patient assessment in the Numeric Pain Scale from entry 
to completion of the MAP 
• MAP participants report reduced pain, which they 
attribute to the MAP  
• Interviews 
• MAP participant data 
• Consumer survey 
• Consumer focus groups 
(H3) Participation in the MAP results 
in enhanced mobility and 
functionality for people with 
MSK health conditions  
• Analysis of MAP participant data shows improvement in 
patient assessment in the Timed Up and Go test score, 
pre- and post-MAP 
• Analysis of MAP participant data shows improvement in 
patient assessment, pre- and post-MAP, in the: 
• Oxford Hip Score (hip conditions) 
• Oxford Knee Score (knee conditions) 
• Lower Extremity Functional Scale (LEFS) (lower 
limbs) 
• Vernon Moir Neck Disability Index (neck) 
• MAP participant data 
• Consumer survey 
• Consumer focus groups 
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Criteria Desired achievements Performance indicators Sources of information 
• Roland Morris Low Back Pain Disability 
Questionnaire (lower back) 
• Quick DASH Disability Symptom Score (arm and 
shoulder) 
• MAP participants report improved mobility and function, 
which they attribute to the MAP  
(H4) Participation in the MAP 
enhances patient ability and 
confidence to self-manage their 
conditions 
• MAP participants have increased understanding about 
their condition 
• MAP participants know how to manage their condition  
• MAP participants rate their confidence in controlling and 
managing their MSK health condition as 7/10 or higher57 
• MAP providers offer effective information, advice and 
resources to support self-management of MSK 
conditions  
• MAP participants report that the information, advice and 
resources meet their needs 
• Analysis of MAP participant data shows improvement in 
patient scores in the Stanford Self Efficacy questionnaire 
from entry to completion of the MAP  
• Interviews 
• Consumer focus groups 
• Consumer survey 
• MAP participant data 
• Virtual provider focus 
groups 
 
57 Adapted from the FNX Corporation and Dartmouth College Tool to Assess Health Confidence. Patients are asked to respond to the question ‘how confident are you 
that you can control and manage most of your health problems?’ by rating their confidence on a scale from 0 (not very confident) to 10 (very confident). A score of 7 
or higher is the desired response. 
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Criteria Desired achievements Performance indicators Sources of information 
(H5) Participation in the MAP 
supports clients’ general health 
and wellbeing  
• Analysis of MAP participant data shows improvement in 
patient assessment in the SF-12 pre- and post-MAP 
• MAP participants report increased ability to participate 
in activities which they enjoy 
• Interviews 
• MAP participant data 
• Consumer survey 
• Consumer focus group 
(H6) Participation in the MAP reduces 
client need for secondary 
healthcare services 
• Analysis of health data for the MAP participant cohort 
shows a pre- and post-MAP reduction in: 
• Initial specialist assessments for hip and knee 
replacement surgeries 
• Demand for hospital physiotherapy services (as 
recorded in the National Non-Admitted Patient 
Collection) 
• Interviews 
• MAP participant data 
• NZ-MOA analysis 
• Virtual provider focus 
groups  
KEQ2: To what extent has the MAP reached its anticipated enrolment and completion rates? 
Reach (R) (R1) MAPs are achieving anticipated 
participant enrolment volumes  
• The 17 MAP pilot projects meet their contracted 
enrolment numbers 
• MAP providers report that enrolment numbers for their 
targeted priority groups (Māori, Pasifika, and those living 
in high deprivation) are meeting expectations 
• Interviews 
• MAP participant data 
(R2) MAPs are achieving anticipated 
completion rates 
• 80% of those who enrol in a MAP complete their 
programme 
• Completion rates for priority groups are comparable to 
the general MAP cohort 
• Interviews 
• MAP participant data 
KEQ3: To what extent is the MAP reducing disparities in access to health services and outcomes? 
Reduction in 
disparities (D) 
(D1) MAP providers implement a 
range of appropriate strategies 
• MAP providers develop and implement a range of 
strategies to reach the priority groups 
• Interviews 
• Document review 
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Criteria Desired achievements Performance indicators Sources of information 
to reach Māori, Pasifika58 and 
those living in high deprivation 59 
(the ‘priority groups’) 
• MAP providers tailor programme delivery to meet the 
needs of the priority groups 
• Virtual provider focus 
groups 
 
(D2) MAP providers effectively reach 
and meet the needs of the 
priority groups  
 
• The priority groups’ participation rates in the MAP are 
comparable to these groups’ population-level rates of 
MSK conditions 
• Māori and Pasifika clients report that the MAP was 
delivered in a culturally appropriate way  
• Interviews 
• MAP participant data 
• Consumer focus groups 
• Virtual focus groups 
• NZ-MOA analysis 
(D3) The priority groups experience 
equity of outcomes to the 
general MAP cohort 
• The priority groups’ achievement of health outcomes 
(desired achievements H1–H6) are comparable to the 
general MAP cohort 
• MAP participant data 
• NZ Census data analysis 




(E1) MAP resources are allocated 
efficiently and effectively 
according to outputs (what was 
delivered) and outcomes (what 
was achieved), providing value 
for money 
 
• Agreed programme outputs are delivered 
• MAP is enabling the achievement of health outcomes 
(desired achievements H1–H6) and productivity gains 
(desired achievement E2)  
• The MAP’s outcomes and impacts are considered by the 
Ministry and sector experts to be value for money  
• MAP providers consider offering the MAP service to be 
of value to their business  
• Interviews 
• Document review 
• MAP participant data  
• Virtual provider focus 
groups 
• NZ-MOA analysis 
 
58 The New Zealand Health Survey 2013/14 shows that Māori and Pasifika adults were 1.3 times more likely to have arthritis than non-Māori and non-Pasifika adults. 
59 Arthritis UK (2014) reports that those living in high deprivation are more likely to report chronic pain, and the pain they experience is likely to be more severe. 
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Criteria Desired achievements Performance indicators Sources of information 
• The overall burden of MSK health conditions, measured 
by health-related quality of life data, is improved over 
time in the MAP cohort 
(E2) The MAP contributes to financial 
savings for both the health 




• Estimated decrease in future demand for health services 
(desired achievement H6) is likely to result in savings for 
the health system 
• MAP participants report reduced costs in medications, 
general practitioner visits, and physiotherapy  
• Interviews 
• Document review 
• MAP participant data  
• MAP consumer survey 
• Virtual provider focus 
groups 
• NZ-MOA analysis 
(E3) Participation in the MAP results 
in increased productivity of the 
MAP cohort 
• Analysis of MSD data shows a decrease in MAP 
participant receipt of government income support 
benefits pre- and post-MAP 
• Analysis of IRD data and consumer reporting shows a 
reduction in income losses due to MSK conditions in the 
MAP cohort pre- and post-MAP 
• MAP participants report fewer days absence from work 
due to their MSK conditions pre- and post-MAP 
• MAP consumer survey 
• Consumer focus group 
• NZ-MOA analysis 
(E4) The MAP is a sustainable 
economic model that is likely to 
remain viable into the future 
• The actual costs to deliver the MAP service, to providers 
and the Ministry, are in line with budgeted costs 
• Economic forecasts suggest that the costs of service 
provision are unlikely to rise substantially in the next 5 
years 
• MAP providers report that they would re-tender for the 
service, should the opportunity become available 
• Interviews 
• Virtual provider focus 
groups 
• NZ-MOA analysis 
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Criteria Desired achievements Performance indicators Sources of information 
KEQ5: How well has the MAP managed patient care? 
Consumer 
experience (C) 
(C1) MAP consumers report that MAP 
services meet their expectations 
against key indicators of 
consumer experience60 
 
• MAP participants report that their MAP provider offers 
acceptable wait times for appointments  
• MAP participants report that their MAP provider’s 
services are affordable and accessible 
• MAP participants report that their MAP provider 
scheduled the services/programmes at convenient times 
(e.g., after work, on weekends) 
• MAP participants report that they are treated with 
respect and dignity by their MAP provider  
• MAP participants report that they have as much 
involvement as wanted in their care decisions 
• MAP consumer survey 
• Consumer focus groups 
(C2) The consumer experience of 
MAP, from entry to exit, is 
focused and streamlined 
 
• MAP providers can articulate how their model of care is 
relevant and customised to the local environment 
• MAP participants have an accurate understanding of 
what the service offers  
• MAP participants report that care is well-coordinated 
across the various providers and services that consumers 
use 
• Interviews 
• Consumer focus groups 
• MAP consumer survey 
• Virtual provider focus 
groups 
 
60 Adapted from the Health Quality and Safety Commission’s Primary Care Patient Experience Survey tool 
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Criteria Desired achievements Performance indicators Sources of information 
(C3) MAP consumers experience 
short-term changes after 
participation in the MAP 
 
• MAP participants report that their health, economic and 
other life circumstances have improved after completing 
the MAP  
• Analysis of MAP participant data shows positive change 
on health indicators pre- and post-MAP 
• Analysis of IDI data shows change on indicators (desired 
achievements H1–H6) and productivity gains (desired 
achievement E2) pre- and post-MAP 
• Consumer focus groups 
• Consumer survey 
• MAP participant data 
• NZ-MOA analysis 
KEQ6: Under what conditions does the programme work best? 
What works best This question will be addressed through synthesis and analysis of all the information collected during the 
course of the evaluation, and by comparing performance of the 17 MAPs against the standards outlined 
above. 
• Interviews 
• Document review 
• MAP participant data 
• Consumer focus groups 
• MAP consumer survey 
• NZ-MOA analysis 
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Evaluation rubrics are tools that provide an assessment framework for the kinds of evidence we 
expect to see at different levels of performance for each of the evaluation criteria and KEQs. The 
rubrics below established the standards against which MAP was evaluated. These identified what 
was considered to have “exceeded expectations”, “met expectations”, was “below expectations”, 
or had “no change” or was “detrimental” under each performance criterion. 
Additionally, all criteria included a category “unable to be determined”, which was used when 
insufficient and/or adequate evidence was available to make a robust evaluative judgement. 
Table 17: MAP evaluation rubric 
Criteria Exceeded 
expectations 
Met expectations Below expectations 
(with some positive 
achievements) 








standards and no 
substantive 
weaknesses.  









some serious, but 
non-fatal, weaknesses 








Health outcomes There is strong 
evidence that 
participation in the 







and reduced need for 
secondary healthcare 
services. 
Participation in the 
MAP results in 
improvement in most 
of the expected 











than expected on one 
or two expected 
outcomes. 
Participation in the 
MAP results in 
improvement in less 








and reduced need for 
secondary healthcare 
services).  
Very few, if 














While some MAP pilot 
sites are meeting the 
anticipated enrolment 
and completion rates, 
in most sites the 
numbers are below 
expectations. 
All, or nearly 
all, of the MAP 











Met expectations Below expectations 
(with some positive 
achievements) 





The MAP is effectively 
reaching and meeting 
the needs of Māori, 
Pasifika and those 
living in high 
deprivation. Health 
and economic 
outcomes for these 
groups are better than 
for the general MAP 
cohort.  
The MAP is mostly 
effective in reaching 
and meeting the 
needs of Māori, 
Pasifika and living in 
high deprivation. 
Health and economic 
outcomes for these 
groups are similar to 
the general MAP 
cohort.  
There is low 
participation in the 
MAP by Māori, 
Pasifika and those 
living in high 
deprivation. 
Achievement of health 
and economic 
outcomes for those 
that do participate are 
lower than for the 
general MAP cohort.  
Very few Māori, 
Pasifika and 




the MAP. For 








MAP cohort.   
Economic impact 
 
There is strong 
evidence that the 





and created financial 
savings for the health 
system. 






and created financial 
savings for the health 
system. 
The MAP has made 
some progress 
towards its expected 
economic outcomes, 
but its impact could 
be enhanced. 
Very few, if 





been achieved.  
Consumer 
experience 
The MAP meets 









is consistently positive 
across all MAPs. 




consumers received a 
streamlined 
experience that 
equips them to self-
manage their 
conditions. There is 
some minor variation 
in the quality of 
consumer experience 
across the MAPs. 
The MAP meets the 
needs and expectation 
of some consumers, 
but many are not 
satisfied with the 
service. The consumer 





that did not equip 
them to self-manage 
their conditions. 
The MAP did 
not meet the 
needs and 
expectations of 





MAP did not 
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APPENDIX D: MAP PROVIDER AND MAP CHARACTERISTICS 









Short ≤ 10 
weeks 




Programme 1              
Programme 2              
Programme 3            
Programme 4              
Programme 5              
Programme 6             
Programme 7             
Programme 8               
Programme 9              
Programme 10           
Programme 11             
Programme 12             
Programme 13              
Programme 14              
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Programme 15              
Programme 16             
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APPENDIX E: MAP EVALUATION CYCLE 2 DATA COLLECTION METHODS 
The following information details the data collection methods used in Cycle 2 of the MAP 
evaluation. 
Key informant interview 
Allen + Clarke interviewed Ministry staff involved in the planning, governance, and management 
of the MAP (e.g., key informants). The interview lasted approximately 90 minutes. We interviewed 
face-to-face, and the interview was semi-structured around an interview guide which addressed 
the evaluation criteria. The interview followed a thorough informed consent process and were 
audio-recorded with permission so that written notes made during the interview could be 
verified. 
Virtual focus group interviews with MAP providers 
Two members of the evaluation team conducted four virtual focus-group interviews using Zoom 
(an online web platform), with key people from all service providers categorised into the four 
programme/provider areas of provider type, delivery type, programme duration and referral 
type. The virtual focus groups were approximately 60 minutes in duration. The virtual focus group 
programme was based on a sub-set of the interview guide questions used in the case studies. 
Participants were able to provide verbal, written feedback both during and after the focus group. 
MAP participant data: Methodological and demographic information 
Methodological information 
An important component of the MAP was to collect health information from all participants at four 
points of their treatment experience: baseline (Time 1); discharge (Time 2); +3 months follow-up 
post-discharge (Time 3); and +12 months follow-up post-discharge (Time 4). MAP providers 
collected this health information and provided it to the Ministry. In turn, the Ministry provided 
the evaluation team with participants’ de-identified data for analysis both across the cohort and 
across the MAPs.  
For this report, data on 4,762 individuals who participated in the MAP were analysed. Of these 
individuals, 21 had participated in more than one MAP (i.e., had gone from one 
provider/programme to another during the course of the evaluation). For the purposes of the 
current analysis, these participants’ data are considered as separate observations (i.e., resulting 
in a total of 4,783 observations analysed). 
For each observation, the following basic clinical data were provided at Time 1:  
• height; 
• clinical diagnosis; 
• referral source (e.g., GP, hospital, self-referral); 
• duration of the condition; and 
• comorbid health conditions.  




• work status; 
• healthcare utilisation; 
• general health-related quality of life (i.e., SF-12 questionnaire; not collected at Time 2); 
• condition-specific health-related quality of life and pain severity; and 
• self-efficacy. 
Condition-specific health-related quality of life measures included the Oxford Knee Score or OKS 
(2,023 patients, 14 programmes); the Oxford Hip Score or OHS (843 patients, 13 programmes); 
the Lower Extremity Function Scale or LEFS (670 patients, 11 programmes); the Roland Morris 
Low Back Pain Disability Questionnaire or RMDQ (1,045 patients, 9 programmes); the QuickDASH 
score for disorders of the arm and shoulder (95 patients, 5 programmes); and the Vernon Moir 
score for neck disorders (28 patients, 3 programmes). See also Section 2.2.1 for further details. 
Data preparation 
Of the 4,783 participants, 3,715 (78 percent) had reported data at Time 2; 3,178 (66 percent) at 
Time 3; and 2,900 (61 percent) at Time 4. Complete data on all variables was less: 4,340 
participants (91 percent) had complete data for Time 1; 3,273 participants (68 percent) at Time 
2; 2,426 (51 percent) participants at Time 3; and 2,131 (45 percent) participants at Time 4. 
Excluding weight, which was not collected for all participants at the later follow-ups, complete 
data were collected from 4,363 participants (91 percent) at Time 1; 3,544 (74 percent) at Time 2; 
3,056 (64 percent) at Time 3; and 2,780 (58 percent) at Time 4. 
Several issues with the raw data required data cleaning to ensure the dataset was correct, 
consistent and usable prior to undertaking any analysis. First, height and weight data were 
entered incorrectly for several patients. Heights of 0 (N =14), 1 (N = 2), 5 (N = 1), and 7.72 (N = 1) 
were considered to be data entry errors and treated as missing data. Recorded heights of between 
1 and 2 (in cm) were assumed to be height in metres and corrected accordingly (N = 29). Seven 
further participants had heights of less than 100 (and calculated BMI > 100), which were treated 
as errors and removed. Recorded weights of 0 (N = 25), 1 (N = 1), 5 (N = 2), and 7.3 (N = 1) were 
assumed to be errors and treated as missing data. Where individuals’ recorded weights changed 
dramatically, these were examined manually to identify likely data errors; some were assumed to 
be recorded in pounds and corrected accordingly. 
Further, diagnosis data was coded as free-text, and as such had inconsistent notation, spelling 
errors, and multiple diagnoses for some participants. Data analysts attempted to group these into 
diagnosis categories by extraction of relevant key words, which was successful for the majority of 
observations; however, it is possible that some coding errors may remain. Diagnoses were coded, 
in priority order, as: 
(1) osteoarthritis, if the recorded diagnosis text included the words ‘OA’ or ‘arthritis’ (or 
obvious misspellings of these); 
(2) back pain if the text contained the words ‘LBP’, ‘back’ or ‘spine’; 
(3) gout, if the text contained ‘gout’; and 
(4) knee/hip pain, not otherwise diagnosed, if the text contained the words ‘knee’ or ‘hip’ and 
none of the previous key words. 
Diagnoses that did not match any of the specified key words were coded as ‘other’. 
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In addition, SF-12 summary score data were incorrectly calculated as the sum of all SF-12 question 
responses. The SF-12 Physical Component Summary (PCS), Mental Component Summary (MCS), 
and SF-6D health utility values were recalculated correctly from the individual SF-12 questions. 
Stanford Self-Efficacy scores and Numerical Pain Rating Scale scores were incorrectly calculated 
as the sum of the question scores, instead of the average, for Programme 15 participants; these 
were recalculated accordingly. 
Last, several participants had a value of less than 0 (N = 269) recorded for the Timed Up and Go 
test; these were treated as missing values. A further 15 participants had a value less than 2; these 
were considered to be errors and treated as missing values. 
The following table provides total MAP participant observations across all data timepoints per 
programme.  
Table 18: Number of MAP participants with recorded data, by programme and time point 









Programme 1 276 179 138 138 
Programme 2 459 301 227 210 
Programme 3 93 64 52 53 
Programme 4 160 96 81 61 
Programme 5 377 306 290 273 
Programme 6 161 133 100 70 
Programme 7 191 170 154 138 
Programme 8  296 257 250 241 
Programme 9 330 228 40 18 
Programme 10 237 201 179 152 
Programme 11 410 266 321 315 
Programme 12 486 423 372 299 
Programme 13 101 98 85 65 
Programme 14 245 202 190 189 
Programme 15 309 246 250 236 
Programme 16 364 316 290 299 
Programme 17 288 229 159 143 
Total 4783 3715 3178 2900 
 
As previously described above and in Section 2.2., data on 12 quantitative health outcome 
measures were collected by MAPs to identify any changes in physical, functional and psychological 
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components of participants’ MSK conditions. The following table presents participants’ mean or 
average scores for each of these measures across all four timepoints. 
 
 
Table 19: Health outcomes at each time point (number of respondents in brackets) 
 
Note: ^ indicates that no data were collected. 
MAP participant data: Regression modelling and data adjustment 
The MAPs recruited patients with different socio-demographic characteristics, from different 
referral sources and clinical history, and with a variety of MSK conditions and baseline health 
status. As these characteristics may be expected to affect participants’ subsequent health 
outcomes as measured at subsequent follow-ups, it was important to adjust for differences in 
baseline characteristics when attempting to compare outcomes across programmes – particularly 
in the absence of any randomly-allocated control group (a non-MAP treatment control group 
would allow for comparison of trajectories between these two similar groups of patients). 
Programme outcomes were estimated using linear regression, controlling for participant-level 
characteristics measured at Time 1: baseline health status (for the outcome measure being 
evaluated), age, gender, length of condition, obesity, diagnosis, socioeconomic deprivation, 
urban/rural residence, ethnicity, comorbid health conditions, and provider-level characteristics 
including whether providers were private rehabilitation agencies or DHB/non-profit 
organisations, whether the programme was delivered individually or in groups of participants, 
the duration of the programme, and the main referral source of the programme. 
Adjusted outcomes for priority groups (Section 2.4 D3) and other demographic groups were then 
calculated using the Effects package in R to predict what would have been observed if the 










Numerical Pain Rating Scale  4.5 (4710) 3.3 (3645) 3.4 (3136) 3.3 (2871) 
Timed Up and Go test  11.0 (4585) 9.0 (3490) ^ ^ 
SF-12 Physical Health Score 36.2 (4651) ^ 40.2 (3089) 39.8 (2820) 
SF-12 Mental Health Score 48.3 (4651) ^ 50.5 (3089) 50.1 (2820) 
SF-6D Health Utility Value 0.65 (4674) ^ 0.70 (3106) 0.70 (2843) 
Stanford Self-Efficacy Score  6.0 (4704) 7.0 (3639) 6.9 (3130) 6.9 (2870) 
Lower Extremity Function Scale  38.7 (667) 47.5 (508) 45.5 (455) 46.0 (442) 
Oxford Hip Score  26.3 (840) 31.5 (670) 31.1 (571) 31.2 (501) 
Oxford Knee Score 26.7 (2019) 31.8 (1575) 32.1 (1347) 32.2 (1210) 
QuickDASH Score 38.5 (80) 27.9 (67) 35.0 (58) 37.3 (53) 
Roland Morris Disability Questionnaire 9.6 (1044) 6.1 (778) 6.5 (687) 6.4 (660) 
Vernon-Moir Index 16.5 (28) 11.5 (25) 13.0 (13) 16.8 (8) 
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participants had the characteristics of the total sample (e.g., the same age distribution etc.). This 
adjustment allowed for unbiased comparison of outcomes across groups.  
 
Economic modelling 
As the design of the MAP did not include a control group to allow us to estimate the programme’s 
effectiveness and cost-effectiveness, the MAP participant data was supplemented with previously-
collected randomised trial data of similar patients (predominantly early- to mid-stage OA) and a 
closely-related exercise therapy intervention (the MOA trial). [Abbott JH, Robertson MC, Chapple 
C, et al. (2013) Manual therapy, exercise therapy, or both, in addition to usual care, for osteoarthritis 
of the hip or knee: a randomized controlled trial. 1: clinical effectiveness, Osteoarthritis and 
Cartilage 21:525-34; Abbott JH, Wilson R, Pinto D, et al. (2019) Incremental clinical effectiveness 
and cost effectiveness of providing supervised physiotherapy in addition to usual medical care in 
patients with osteoarthritis of the hip or knee: 2-year results of the MOA randomised controlled trial, 
Osteoarthritis and Cartilage 27:424-34] 
The MOA trial was a randomised controlled trial investigating the clinical- and cost-effectiveness 
of providing an individually tailored, supervised exercise physiotherapy intervention for people 
with hip or knee osteoarthritis. Participants were randomly assigned to either a ‘usual care’ 
control group, in which they continued to receive the usual medical care provided by their GP and 
other healthcare providers; an exercise therapy intervention group, who participated in a multi-
model, supervised programme of warmup/aerobic, muscle strengthening, muscle stretching, and 
neuromuscular exercises delivered by a physiotherapist, as well as a home exercise programme 
to be completed three times per week; or manual therapy or combined manual and exercise 
therapy interventions, which were not considered in this analysis. 
Health outcomes at baseline and follow-ups in the MAP and MOA trial were compared graphically 
to determine the baseline similarity and health outcome trajectories of the cohorts. Data collected 
in a comparable manner in both data sources and used for comparative analysis were self-rated 
pain (NPRS), Timed Up and Go test, SF-12 physical, mental, and general health-related quality of 
life, and the number of GP visits made for participants’ MSK conditions. 
To adjust for differences in baseline characteristics between samples, data from the MAP and the 
MOA trial were pooled and linear regression models estimated for each outcome. Baseline 
covariates used in the regression models were restricted to those measured in a similar manner 
in both data sources: age, gender, baseline health outcomes, and BMI. 
Over the follow-up period, MAP participants had rapid improvements up to Time 3 on most 
outcomes that were similar to or greater than those seen in the MOA trial exercise therapy group, 
but slightly smaller long-term improvements at Time 4. MAP participants’ outcomes for most 
measures and across all time points were better than the MOA trial usual care control group. 
Further, MAP participants’ pain levels (NPRS) improved at a similar rate to MOA trial exercise 
therapy group participants until Time 2 and remained approximately constant thereafter, while 
the MOA trial groups showed some continued improvement in pain until a two-year follow-up. 
TU&G times improved rapidly for MAP participants from Time 1 to Time 2, at a similar rate to that 
seen in the MOA trial exercise therapy group. The TU&G test was not used at later follow-up points 
in the MAP, so no longer-term comparison can be made. 
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SF-12 PCS scores also improved rapidly from Time 1 to Time 3 in the MAP participant cohort at a 
similar rate as the MOA trial exercise therapy group but declined somewhat by Time 4. SF-12 MCS 
scores were slightly worse at baseline in the MAP participant cohort than the MOA trial groups, 
improved slightly at Time 3 and remained approximately constant at Time 4. SF-6D values were 
slightly worse at baseline in the MAP cohort, improved at a similar rate to the MOA trial exercise 
therapy group at Time 3, and deteriorated slightly by Time 4. 
The number of reported GP visits was the only healthcare measure comparable between the MAP 
and MOA trial cohorts: MAP participants reported fewer GP visits than both MOA trial groups at 
all follow-up points (Figure 31).61 
 
 
61 The data shows improvements in the usual care group of the MOA trial on some health outcomes. This is 
likely due to mean reversion. Outcomes in osteoarthritis fluctuate over time, and as people are more likely 
to be recruited into the programmes at a point when they have more severe symptoms, they tend to improve 
afterwards (at least over the short term) regardless of the effectiveness or otherwise of treatment. 
Figure 31: Change in health outcomes from baseline to follow-up, MAP and MOA trial samples 
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Regression findings showed that the MAP’s ‘treatment effectiveness’ (i.e., improvement relative 
to usual care) was positive for most outcomes, but smaller than the trial exercise therapy 
intervention.62 
Overall, the MAP was estimated to have a relative effectiveness on health-related quality of life of 
70 percent compared to the MOA trial exercise therapy intervention.63,64 
Simulation modelling 
The cost-effectiveness of the MAP was estimated using a previously-validated computer 
simulation model (the NZ-MOA model) of the disease course, health losses, and treatment costs of 
osteoarthritis in the NZ population. [Wilson R, Abbott JH (2018) Development and validation of a 
new population-based simulation model of osteoarthritis in New Zealand, Osteoarthritis and 
Cartilage 26:531-9.] In brief, the NZ-MOA model is a state-transition microsimulation model of the 
disease course of OA in the NZ population, including radiographic disease incidence and 
progression, fluctuation and gradual progression of disease symptoms and health-related quality 
of life impacts, and treatment pathways and their costs and health-related quality of life effects. 
By running the same simulated cohort through different hypothetical treatment pathways, the 
incremental costs and health gains of treatments can be estimated. 
For evaluation of the MAP, the model was specified for a baseline population matching the age, 
gender, ethnic, and obesity distribution of the MAP cohort. All participants were assumed to have 
osteoarthritis at baseline, with disease progression and impact on health-related quality of life 
(without the impact of MAP participation) similar to those of all people with osteoarthritis in the 
NZ population. The ‘treatment effect’, or the incremental effect of participation in the MAP relative 
to this population trajectory, was estimated using the regression models specified in the pooled 
MAP and MOA trial data. Health-related quality of life was measured and valued using the SF-6D 
instrument, derived from the SF-12 data collected in both the MAP and MOA trial samples. As the 
data collected in the MAP could not be used to estimate longer-term healthcare cost impacts (e.g. 
cost savings due to reduction in other health service use), it was assumed that these would be 
proportional to the cost savings observed in long-term follow-up of the MOA trial participants, 
adjusted for differences in the relative effectiveness of the two interventions (as measured by 
general health-related quality of life). 
For the primary analysis, data from all MAP participants were used to estimate model input 
parameters. As a sensitivity analysis, since the NZ-MOA model is designed to model the course of 
 
62 Regression models were adjusted for differences in baseline characteristics between groups. 
63 MAP data could not be used to estimate longer-term healthcare costs (e.g., cost savings due to reductions 
in other health service use). An assumption was therefore made that costs would be proportional to savings 
observed in the long-term follow-up of MOA participants (i.e., 70 percent of cost savings observed in the 
MOA trial exercise therapy group aligned with 70 percent relative effectiveness in overall health-related 
quality of life outcomes). 
64 Cost savings were assumed to be realised from the second year and onwards (as only small reductions in 
health service use were observed in Time 4 data, which is consistent with MOA trial results). Further, direct 
programme costs were used for the first year of MAP only, and were based on budgeted per-participant 
costs using provider contracts. The budgeted per-participant costs also include an allocation for data 
collection to support programme evaluation, which would not be required in an operational programme. 
Results may therefore not reflect the actual costs of service delivery. 
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osteoarthritis only, treatment effects were estimated using only data from MAP participants with 
a diagnosis of OA (approximately 77 percent of the MAP cohort). 
The simulated cohort was run through two scenarios, reflecting ‘usual care’ assumed to be 
received in the absence of MAP participation, and observed and projected outcomes for 
participants having been through the MAP; the difference between these scenarios gives the 
estimated incremental effect of MAP participation. 
Projected impacts of the MAP were estimated for follow-up time horizons of one, three, five, 10, 
and 15 years to look at short-, medium-, and long-term impacts. The outcome measures evaluated 
for the cost-effectiveness analysis were health gains (quality-adjusted life years, or QALYs; a 
measure combining both quality and quantity of time spent with health impairments/gains), total 
healthcare costs, and incremental net monetary benefit (INMB). The INMB is a measure of the 
overall cost-effectiveness of a treatment from the perspective of the healthcare system, assuming 
a given level of willingness-to-pay (WTP) for healthcare to achieve a given health gain. There are 
several methods available to choose this WTP level and little consensus on what approach should 
be used; for this analysis, a value of $57,500 per QALY gained, equivalent to NZ GDP per capita in 
2017, was used (as recommended by the WHO). 
Uncertainty in the simulation modelling results is assessed using probabilistic sensitivity analysis 
(PSA). This involves re-running the model for a large number of simulated cohorts; in each 
separate simulation run, the parameter inputs (treatment effects on SF-6D health utility, 
healthcare costs, and BMI) are drawn as random values from the distributions estimated by the 
regression models. Each simulation run therefore gives a different resulting cost-effectiveness 
estimate, based on the uncertainty in model inputs, and the resulting distribution of cost-
effectiveness results is used to estimate the uncertainty in these outcomes. The uncertainty 
analysis is used to generate 90% uncertainty intervals around each estimated result, as well as to 
construct a cost-effectiveness plane to visually examine the uncertainty in the key outcomes of 
incremental healthcare costs, QALY gains, and net monetary benefit. 
Consumer survey 
An anonymous survey of all MAP consumers was administered using SurveyMonkey and a paper-
based version of the survey to the entire MAP cohort65 during Cycle 1 to obtain quantifiable data 
on the prevalence of the views, issues and impacts regarding the consumer experience of the MAP. 
The survey asked questions about each of the evaluation themes using mainly closed questions 
with some open-text responses. In total, 1,019 clients from a possible 3,453 (29.5 percent) 
completed the survey.  There were clients from 17 Mobility Action Programme (MAP) providers. 
The majority (57.3 percent) completed the survey using paper with remaining online (42.7 
percent). Data was initially aggregated and cleaned using Microsoft Excel and key variables were 
transformed to binary indicators for analysis (Table 20). 
Logistic regression modelling 
A logistic regression model in SPSS was used to test for differences by age, gender, ethnicity, and 
provider characteristics (Table 20Error! Reference source not found.) for each of the outcome v
ariables. If there were less than 10 responses in one of the two outcome categories in the proposed 
model, a logistic regression was not attempted. 
 
65 This includes both completers and non-completers.  
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Table 20. Logistic Regression Coding. 
Variable Category Coding 
Referral GP 1 
Not GP 0 
Age 18 to 60 (working age) 1 
61+ 0 
Ethnicity Māori 1 
Not Māori 0 
MAP type Private rehab 1 
Mixed 0 
Duration Short 1 
Long 0 
Delivery method Group or mix 1 
Individual 0 





There were more females (71%) than males and 28% were 60 years of age or younger. Fewer 
Māori (6.6%) and Pacific than may be expected responded (5.1%). 
Table 21: Consumer survey demographic breakdown: Age x Gender. 
Age Female Gender diverse Male Prefer not to say Missing Grand Total 
18 - 30 years 7     7 
31 - 40 years 12  4   16 
41 - 50 years 41  19   60 
51 - 60 years 150  43   193 
61 - 70 years 265 1 107 1 2 376 
71 - 80 years 189  91  4 284 
81 - 90 years 20  21  3 44 
91 years or more 1     1 
Prefer not to say 1     1 
Missing     37 37 




Table 22. Consumer survey demographic breakdown: Ethnicity (counts and percentages). 
Ethnicity Count 
Māori 67 (6.6%) 
Pacific peoples 52 (5.1%) 
Asian 13 (1.3%) 
Indian 2 (0.2%) 
MELAA 1 (0.1%) 
European 837 (82%) 
Other 1 (0.1%) 
Did not answer 46 (4.5%) 
 
Table 23. Time since MAP completion (counts and percentages). 
 Time since completion Count 
Still doing the MAP 127 (13%) 
Less than 3 months ago 232 (23%) 
Less than 12 months ago 387 (39%) 
More than 12 months ago 259 (26%) 
The overall response rate saw almost a third of the possible 3,453 clients respond to the survey, 
this varied by provider with very few clients from Programme 9 (7 clients) and Programme 11 (1 
client) responding. 
Table 24.  Consumer survey provider response rates (counts and percentage of that programme’s total 
participant numbers) 
Provider Count 
Programme 1 30 (18%) 
Programme 2 39 (10%) 
Programme 3 20 (38%) 
Programme 4 15 (13%) 
Programme 5 106 (29%) 
Programme 6  71 (64%) 
Programme 7 67 (81%) 
Programme 8 72 (37%) 
Programme 9  7 (7.4%) 
Programme 10  67 (67%) 
Programme 11  1 (0.3%) 
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Provider Count 
Programme 12 142 (30%) 
Programme 13  35 (44%) 
Programme 14  64 (38%) 
Programme 15 34 (47%) 
Programme 16 85 (27%) 
Programme 17  109 (43%) 
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